FGFR1-Related Hypogonadotropic Hypogonadism

Mendelian MONDO:0007844 Pathograph 3 FGFR1-related disorder Disorders of puberty

Hypogonadotropic hypogonadism 2 with or without anosmia (Kallmann syndrome 2) is caused by loss-of-function mutations in FGFR1. It is characterized by isolated gonadotropin-releasing hormone (GnRH) deficiency leading to absent or incomplete puberty, low sex steroid levels, and infertility. Approximately 60% of individuals have anosmia (Kallmann syndrome) and 40% have a normal sense of smell (normosmic IGD). Infant boys may present with micropenis and cryptorchidism. Extra-reproductive findings can include cleft lip/palate, tooth agenesis, skeletal or digital anomalies, and other variable FGF-pathway features. FGFR1 signaling is required for GnRH neuron development and migration from the olfactory placode to the hypothalamus during embryonic development.

Ask OpenScientist

Ask a research question about FGFR1-Related Hypogonadotropic Hypogonadism. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

2
Inheritance
2
Pathophys.
13
Phenotypes
3
Pathograph
1
Genes
6
Treatments
2
Subtypes
11
References
1
Deep Research
👪

Inheritance

2
Autosomal dominant HP:0000006
FGFR1-related hypogonadotropic hypogonadism most often follows autosomal dominant inheritance with incomplete penetrance and marked variable expressivity. Affected families can include anosmic Kallmann syndrome, normosmic IHH, delayed puberty, anosmia-only relatives, and asymptomatic carriers.
Autosomal dominant inheritance
Show evidence (3 references)
PMID:12627230 SUPPORT Human Clinical
"We took advantage of overlapping interstitial deletions at chromosome 8p11-p12 in two individuals with contiguous gene syndromes and defined an interval of roughly 540 kb associated with a dominant form of Kallmann syndrome, KAL2."
The original FGFR1 discovery paper localizes and establishes dominant KAL2 disease.
PMID:18985070 SUPPORT Other
"Mutations in FGFR1 or FGF8, encoding fibroblast growth factor receptor-1 and fibroblast growth factor-8, respectively, underlie an autosomal dominant form with incomplete penetrance."
This Kallmann syndrome review explicitly adds incomplete penetrance for FGFR1/FGF8-associated autosomal dominant disease.
PMID:16764984 SUPPORT Human Clinical
"we found an even wider spectrum of reproductive function within pedigrees carrying an FGFR1 mutation ranging from IHH to delayed puberty to normal reproductive function (anosmia only or asymptomatic carriers)."
FGFR1 pedigrees demonstrate variable expressivity and unaffected or olfactory-only carriers.
Oligogenic inheritance and modifier variants HP:0010983
FGFR1 variants may act with variants in other IGD/CHH genes as digenic or oligogenic contributors, which helps explain intrafamilial variability and complicates recurrence-risk counseling.
Oligogenic inheritance
Show evidence (2 references)
PMID:17235395 SUPPORT Human Clinical
"Therefore, 2 different gene defects can synergize to produce a more severe phenotype in IHH families than either alone."
This family study directly supports digenic modification of IHH severity involving FGFR1.
PMID:23643382 SUPPORT Human Clinical
"Mutations in genes encoding components of the FGF pathway are associated with complex modes of CHH inheritance and act primarily as contributors to an oligogenic genetic architecture underlying CHH."
FGF-pathway cohort data support oligogenic inheritance architecture around FGFR1 signaling.
◆

Subtypes

2
Kallmann syndrome type 2 (FGFR1-related IGD with anosmia)
FGFR1-related isolated GnRH deficiency with impaired smell, reflecting the Kallmann syndrome branch of hypogonadotropic hypogonadism 2 with or without anosmia.
Show evidence (1 reference)
PMID:20301509 SUPPORT Other
"IGD is associated with a normal sense of smell (normosmic IGD) in approximately 40% of affected individuals and an impaired sense of smell (Kallmann syndrome) in approximately 60%."
GeneReviews supports separating anosmic Kallmann and normosmic IGD presentations.
Normosmic FGFR1-related idiopathic hypogonadotropic hypogonadism
FGFR1-related isolated GnRH deficiency with normal olfactory-system imaging or smell testing, demonstrating that FGFR1 pathogenic variants can cause normosmic IHH as well as Kallmann syndrome.
Show evidence (1 reference)
PMID:16606836 SUPPORT Human Clinical
"We conclude that loss-of-function mutations in FGFR1 cause nIHH with normal MRI of the olfactory system."
This FGFR1 cohort directly supports a normosmic IHH subtype.
⚙

Pathophysiology

2
Impaired GnRH neuron migration
FGFR1 loss-of-function reduces FGF receptor signaling during GnRH neuron ontogeny and migration from the olfactory placode to the hypothalamus. This results in deficient hypothalamic GnRH secretion and consequent failure of pituitary gonadotropin release. In individuals with anosmia, olfactory bulb development is also impaired.
Hypothalamic GnRH neuron link
Neuron migration link ↓ DECREASED Fibroblast growth factor receptor signaling pathway link ↓ DECREASED Olfactory bulb development link ↓ DECREASED Gonadotropin secretion link ↓ DECREASED
Downstream
GnRH deficiency and hypogonadism
Show evidence (2 references)
PMID:12627230 SUPPORT Human Clinical
"We establish here that loss-of-function mutations in FGFR1 underlie KAL2 whereas a gain-of-function mutation in FGFR1 has been shown to cause a form of craniosynostosis."
The original discovery paper supports FGFR1 loss of function as the causal lesion in Kallmann syndrome type 2.
PMID:18596921 SUPPORT Human Clinical
"While loss-of-function mutations in FGF receptor 1 (FGFR1) cause human GnRH deficiency, to date no specific ligand for FGFR1 has been identified in GnRH neuron ontogeny."
This establishes the FGFR1 signaling context for human GnRH deficiency and motivates FGF8-FGFR1 pathway modeling.
GnRH deficiency and hypogonadism
Deficiency of hypothalamic GnRH leads to inappropriately low serum gonadotropins (LH and FSH) and consequently low sex steroid levels. This results in absent or incomplete pubertal development, infertility, and decreased bone mineral density.
Gonadotropin secretion link ↓ DECREASED
Show evidence (1 reference)
PMID:20301509 SUPPORT Human Clinical
"Isolated gonadotropin-releasing hormone (GnRH) deficiency (IGD) is characterized by inappropriately low serum concentrations of the gonadotropins LH (luteinizing hormone) and FSH (follicle-stimulating hormone) in the presence of low circulating concentrations of sex steroids."
Defines the core endocrine defect of IGD.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for FGFR1-Related Hypogonadotropic Hypogonadism Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

13
Ear 1
Hearing impairment OCCASIONAL Hearing impairment (HP:0000365)
Show evidence (1 reference)
PMID:31748124 PARTIAL Human Clinical
"In addition to hypogonadotropic hypogonadism, 44.4% (8/18) patients exhibited other clinical deformities, including dental agenesis (3/18, 16.7%), hearing loss (3/18, 16.7%), and hand malformation (2/18, 11.1%)."
This supports hearing loss in a combined FGFR1/FGF8/FGF17 mutation cohort, so the evidence is partial for FGFR1-specific attribution.
Endocrine 2
Delayed puberty OBLIGATE Delayed puberty (HP:0000823)
Show evidence (1 reference)
PMID:20301509 SUPPORT Human Clinical
"Adolescents and adults with IGD have clinical evidence of hypogonadism and incomplete sexual maturation on physical examination."
Confirms delayed puberty as a cardinal feature.
Hypogonadism OBLIGATE Hypogonadism (HP:0000135)
Show evidence (1 reference)
PMID:20301509 SUPPORT Human Clinical
"Adult males with IGD tend to have prepubertal testicular volume (i.e., <4 mL), absence of secondary sexual features (e.g., facial and axillary hair growth, deepening of the voice), decreased muscle mass, diminished libido, erectile dysfunction, and infertility."
Describes the hypogonadal phenotype in adult males.
Genitourinary 4
Micropenis FREQUENT Micropenis (HP:0000054)
Show evidence (1 reference)
PMID:20301509 SUPPORT Human Clinical
"Infant boys with congenital IGD often have micropenis and cryptorchidism."
Micropenis is a recognized feature in infant boys with congenital IGD.
Cryptorchidism FREQUENT Cryptorchidism (HP:0000028)
Show evidence (1 reference)
PMID:20301509 SUPPORT Human Clinical
"Infant boys with congenital IGD often have micropenis and cryptorchidism."
Cryptorchidism is a recognized feature in infant boys with congenital IGD.
Primary amenorrhea VERY_FREQUENT Primary amenorrhea (HP:0000786)
Show evidence (1 reference)
PMID:20301509 SUPPORT Human Clinical
"Adult females have little or no breast development and primary amenorrhea."
Confirms primary amenorrhea as a feature in affected females.
Infertility OBLIGATE Infertility (HP:0000789)
Show evidence (1 reference)
PMID:20301509 SUPPORT Human Clinical
"diminished libido, erectile dysfunction, and infertility."
Infertility is a core feature of IGD.
Head and Neck 3
Anosmia FREQUENT Anosmia (HP:0000458)
Show evidence (1 reference)
PMID:20301509 SUPPORT Human Clinical
"IGD is associated with a normal sense of smell (normosmic IGD) in approximately 40% of affected individuals and an impaired sense of smell (Kallmann syndrome) in approximately 60%."
Establishes anosmia frequency at approximately 60%.
Orofacial cleft OCCASIONAL Orofacial cleft (HP:0000202)
Show evidence (2 references)
PMID:16606836 SUPPORT Human Clinical
"Q680X in a nIHH male with cleft lip/palate and missing teeth, his brother with nIHH, and his father with delayed puberty."
An FGFR1 loss-of-function family included a normosmic IHH male with cleft lip/palate and missing teeth.
PMID:15605412 SUPPORT Human Clinical
"In this study, unilateral renal agenesis and bimanual synkinesia were exclusively found associated with KAL1mutations, cleft palate and dental agenesia with FGFR1mutations."
A KAL1/FGFR1 mutation cohort associated cleft palate with FGFR1 rather than KAL1.
Tooth agenesis OCCASIONAL Tooth agenesis (HP:0009804)
Show evidence (2 references)
PMID:16606836 SUPPORT Human Clinical
"(P722H and N724K) in an nIHH male missing two teeth and his mother with isolated hyposmia; and (iii) Q680X in a nIHH male with cleft lip/palate and missing teeth"
FGFR1 mutation carriers in normosmic/mixed pedigrees had missing teeth.
PMID:15605412 SUPPORT Human Clinical
"In this study, unilateral renal agenesis and bimanual synkinesia were exclusively found associated with KAL1mutations, cleft palate and dental agenesia with FGFR1mutations."
A KAL1/FGFR1 mutation cohort associated dental agenesis with FGFR1 rather than KAL1.
Musculoskeletal 1
Decreased bone mineral density FREQUENT Reduced bone mineral density (HP:0004349)
Show evidence (1 reference)
PMID:20301509 SUPPORT Human Clinical
"Prevention of secondary complications: Optimal calcium and vitamin D intake should be encouraged and specific treatment for decreased bone mass as needed."
Indicates decreased bone mass as a secondary complication requiring management.
Growth 1
Absent pubertal growth spurt VERY_FREQUENT Growth abnormality (HP:0001507)
Show evidence (1 reference)
PMID:20301509 SUPPORT Human Clinical
"Although skeletal maturation is delayed, the rate of linear growth is usually normal except for the absence of a distinct pubertal growth spurt."
Describes the specific growth pattern in IGD.
Other 1
Oligodactyly and skeletal malformations Oligodactyly (HP:0012165)
Show evidence (1 reference)
PMID:23154428 SUPPORT Human Clinical
"Three patients presented with skeletal abnormalities, i.e. spine (hemivertebra and butterfly vertebra) and limb (oligodactyly of the feet, fusion of the 4th and 5th metacarpal bones) malformations in two patients and one patient, respectively."
This FGFR1 mutation cohort directly reports limb and spine skeletal malformations including oligodactyly.
🧬

Genetic Associations

1
FGFR1 loss-of-function mutations (Causative)
Show evidence (3 references)
PMID:12627230 SUPPORT Human Clinical
"We establish here that loss-of-function mutations in FGFR1 underlie KAL2 whereas a gain-of-function mutation in FGFR1 has been shown to cause a form of craniosynostosis."
This is direct evidence that FGFR1 loss-of-function mutations cause Kallmann syndrome type 2.
PMID:16606836 SUPPORT Human Clinical
"These mutations also account for some of the mixed pedigrees, thus challenging the current idea that KS and nIHH are distinct entities."
FGFR1 mutations can underlie mixed Kallmann and normosmic IHH pedigrees.
PMID:16764984 SUPPORT Human Clinical
"A wide spectrum of reproductive function was observed among KS probands including: (1) a severe phenotype demonstrated by microphallus, cryptorchidism, no pubertal development, undetectable serum gonadotropins and low serum testosterone (T) and inhibin B; (2) partial pubertal development; (3)..."
This FGFR1 cohort supports the broad reproductive severity range and possible reversal.
💊

Treatments

6
Testosterone or hCG therapy for male pubertal induction
Action: hormone replacement therapy Ontology label: Pharmacotherapy NCIT:C15986
Gradually increasing doses of testosterone, or hCG in selected cases, induce and maintain male secondary sex characteristics. Testosterone alone does not induce spermatogenesis, so fertility planning should be addressed separately.
Show evidence (1 reference)
PMID:20301509 SUPPORT Other
"gradually increasing doses of testosterone or human chorionic gonadotropin (hCG) injections in males or estrogen and progestin in females"
GeneReviews describes testosterone or hCG as male pubertal induction therapy.
Estrogen and progestin therapy for female pubertal induction
Action: hormone replacement therapy Ontology label: Pharmacotherapy NCIT:C15986
Gradually escalating estrogen with later progestin exposure induces and maintains female secondary sex characteristics, supports uterine/endometrial health, and helps protect bone health in affected females.
Show evidence (1 reference)
PMID:20301509 SUPPORT Other
"gradually increasing doses of testosterone or human chorionic gonadotropin (hCG) injections in males or estrogen and progestin in females"
GeneReviews explicitly names estrogen and progestin therapy for female pubertal induction.
Fertility induction with gonadotropins or pulsatile GnRH
Action: gonadotropin or pulsatile GnRH fertility therapy Ontology label: pharmacotherapy MAXO:0000058
Combined gonadotropin therapy (hCG with hMG or recombinant FSH) or pulsatile GnRH therapy stimulates spermatogenesis or folliculogenesis when fertility is desired; IVF may be considered if conception fails despite gametogenesis or ovulation induction.
Show evidence (2 references)
PMID:20301509 SUPPORT Other
"to stimulate spermatogenesis or folliculogenesis, either combined gonadotropin therapy"
GeneReviews identifies combined gonadotropin and pulsatile GnRH therapy as fertility-induction options.
PMID:31748124 SUPPORT Human Clinical
"hCG/hMG therapy was effective in promoting sexual development in IHH patients with FGFR1, FGF8, and FGF17 mutations."
This mutation-positive IHH cohort supports hCG/hMG treatment response in an FGF-pathway group including FGFR1.
Bone health monitoring and treatment
Action: supportive care MAXO:0000950
Long-term management should include calcium and vitamin D optimization, monitoring bone mineral density, and treating decreased bone mass when present, especially after delayed diagnosis or treatment gaps.
Show evidence (2 references)
PMID:20301509 SUPPORT Other
"Optimal calcium and vitamin D intake should be encouraged and specific treatment for decreased bone mass as needed."
GeneReviews directly supports bone-health prevention and treatment.
PMID:20301509 SUPPORT Other
"In individuals with confirmed IGD, monitor at regular intervals: serum sex steroid levels (to guide optimal hormone replacement); bone mineral density."
GeneReviews supports monitoring bone mineral density in confirmed IGD.
Psychosocial support and care coordination
Action: supportive care MAXO:0000950
Comprehensive care should address delayed-puberty distress, body image, psychosexual development, adherence, transition to adult endocrine care, peer support, and referral for mental health services when needed.
Show evidence (1 reference)
PMID:31333578 SUPPORT Other
"This review provides a summary of the psychological aspects of CHH/KS and outlines an approach to comprehensive care that spans medical management as well as appropriate attention, care and referrals to peer-to-peer support and mental health services to ameliorate the psychological aspects of CHH/KS."
This CHH/Kallmann review supports explicit psychosocial and mental-health support in care planning.
Genetic and reproductive counseling
Action: genetic counseling MAXO:0000079
Counseling should cover autosomal dominant inheritance with incomplete penetrance, variable expressivity, de novo occurrence, oligogenic/modifier variants, recurrence risk based on family history and molecular results, and the possibility of transmitting FGFR1 or FGF-pathway variants after successful fertility treatment.
Show evidence (2 references)
PMID:20301509 SUPPORT Other
"Almost all IGD-related genes have also been associated with indeterminate or oligogenic inheritance. Recurrence risk counseling is based on family history and the results of molecular genetic testing when available."
GeneReviews supports counseling around oligogenic inheritance and recurrence risk.
PMID:31748124 SUPPORT Human Clinical
"hCG/hMG therapy was effective to acquire fertility for patients with FGFR1, FGF8, and FGF17 mutations but has a risk of transmitting the mutations and IHH to the next generation."
This supports reproductive counseling after fertility induction in FGF-pathway mutation carriers.
{ }

Source YAML

click to show 
name: FGFR1-Related Hypogonadotropic Hypogonadism
creation_date: '2026-04-04T12:00:00Z'
updated_date: '2026-04-04T18:00:00Z'
category: Mendelian
description: >-
  Hypogonadotropic hypogonadism 2 with or without anosmia (Kallmann syndrome 2) is caused
  by loss-of-function mutations in FGFR1. It is characterized by isolated gonadotropin-releasing
  hormone (GnRH) deficiency leading to absent or incomplete puberty, low sex steroid levels,
  and infertility. Approximately 60% of individuals have anosmia (Kallmann syndrome) and
  40% have a normal sense of smell (normosmic IGD). Infant boys may present with micropenis
  and cryptorchidism. Extra-reproductive findings can include cleft lip/palate, tooth agenesis,
  skeletal or digital anomalies, and other variable FGF-pathway features. FGFR1 signaling
  is required for GnRH neuron development and migration from the olfactory placode to the
  hypothalamus during embryonic development.
disease_term:
  preferred_term: hypogonadotropic hypogonadism 2 with or without anosmia
  term:
    id: MONDO:0007844
    label: hypogonadotropic hypogonadism 2 with or without anosmia
parents:
- FGFR1-related disorder
- Disorders of puberty
has_subtypes:
- name: Kallmann
  display_name: Kallmann syndrome type 2 (FGFR1-related IGD with anosmia)
  description: >-
    FGFR1-related isolated GnRH deficiency with impaired smell, reflecting the
    Kallmann syndrome branch of hypogonadotropic hypogonadism 2 with or without
    anosmia.
  evidence:
  - reference: PMID:20301509
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "IGD is associated with a normal sense of smell (normosmic IGD) in approximately 40% of affected individuals and an impaired sense of smell (Kallmann syndrome) in approximately 60%."
    explanation: GeneReviews supports separating anosmic Kallmann and normosmic IGD presentations.
- name: Normosmic IHH
  display_name: Normosmic FGFR1-related idiopathic hypogonadotropic hypogonadism
  description: >-
    FGFR1-related isolated GnRH deficiency with normal olfactory-system imaging
    or smell testing, demonstrating that FGFR1 pathogenic variants can cause
    normosmic IHH as well as Kallmann syndrome.
  evidence:
  - reference: PMID:16606836
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We conclude that loss-of-function mutations in FGFR1 cause nIHH with normal MRI of the olfactory system."
    explanation: This FGFR1 cohort directly supports a normosmic IHH subtype.
inheritance:
- name: Autosomal dominant
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  description: >-
    FGFR1-related hypogonadotropic hypogonadism most often follows autosomal
    dominant inheritance with incomplete penetrance and marked variable
    expressivity. Affected families can include anosmic Kallmann syndrome,
    normosmic IHH, delayed puberty, anosmia-only relatives, and asymptomatic
    carriers.
  evidence:
  - reference: PMID:12627230
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We took advantage of overlapping interstitial deletions at chromosome 8p11-p12 in two individuals with contiguous gene syndromes and defined an interval of roughly 540 kb associated with a dominant form of Kallmann syndrome, KAL2."
    explanation: The original FGFR1 discovery paper localizes and establishes dominant KAL2 disease.
  - reference: PMID:18985070
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Mutations in FGFR1 or FGF8, encoding fibroblast growth factor receptor-1 and fibroblast growth factor-8, respectively, underlie an autosomal dominant form with incomplete penetrance."
    explanation: This Kallmann syndrome review explicitly adds incomplete penetrance for FGFR1/FGF8-associated autosomal dominant disease.
  - reference: PMID:16764984
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "we found an even wider spectrum of reproductive function within pedigrees carrying an FGFR1 mutation ranging from IHH to delayed puberty to normal reproductive function (anosmia only or asymptomatic carriers)."
    explanation: FGFR1 pedigrees demonstrate variable expressivity and unaffected or olfactory-only carriers.
- name: Oligogenic inheritance and modifier variants
  inheritance_term:
    preferred_term: Oligogenic inheritance
    term:
      id: HP:0010983
      label: Oligogenic inheritance
  description: >-
    FGFR1 variants may act with variants in other IGD/CHH genes as digenic or
    oligogenic contributors, which helps explain intrafamilial variability and
    complicates recurrence-risk counseling.
  evidence:
  - reference: PMID:17235395
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Therefore, 2 different gene defects can synergize to produce a more severe phenotype in IHH families than either alone."
    explanation: This family study directly supports digenic modification of IHH severity involving FGFR1.
  - reference: PMID:23643382
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mutations in genes encoding components of the FGF pathway are associated with complex modes of CHH inheritance and act primarily as contributors to an oligogenic genetic architecture underlying CHH."
    explanation: FGF-pathway cohort data support oligogenic inheritance architecture around FGFR1 signaling.
pathophysiology:
- name: Impaired GnRH neuron migration
  description: >-
    FGFR1 loss-of-function reduces FGF receptor signaling during GnRH neuron
    ontogeny and migration from the olfactory placode to the hypothalamus. This
    results in deficient hypothalamic GnRH secretion and consequent failure of
    pituitary gonadotropin release. In individuals with anosmia, olfactory bulb
    development is also impaired.
  gene:
    preferred_term: FGFR1
    description: Fibroblast growth factor receptor 1, required for GnRH neuron migration and olfactory bulb development.
    modifier: DECREASED
    term:
      id: hgnc:3688
      label: FGFR1
  cell_types:
  - preferred_term: Hypothalamic GnRH neuron
    term:
      id: CL:0011111
      label: hypothalamic gonadotropin-releasing hormone neuron
  biological_processes:
  - preferred_term: Neuron migration
    term:
      id: GO:0001764
      label: neuron migration
    modifier: DECREASED
  - preferred_term: Fibroblast growth factor receptor signaling pathway
    term:
      id: GO:0008543
      label: fibroblast growth factor receptor signaling pathway
    modifier: DECREASED
  - preferred_term: Olfactory bulb development
    term:
      id: GO:0021772
      label: olfactory bulb development
    modifier: DECREASED
  - preferred_term: Gonadotropin secretion
    term:
      id: GO:0032274
      label: gonadotropin secretion
    modifier: DECREASED
  evidence:
  - reference: PMID:12627230
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We establish here that loss-of-function mutations in FGFR1 underlie KAL2 whereas a gain-of-function mutation in FGFR1 has been shown to cause a form of craniosynostosis."
    explanation: The original discovery paper supports FGFR1 loss of function as the causal lesion in Kallmann syndrome type 2.
  - reference: PMID:18596921
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "While loss-of-function mutations in FGF receptor 1 (FGFR1) cause human GnRH deficiency, to date no specific ligand for FGFR1 has been identified in GnRH neuron ontogeny."
    explanation: This establishes the FGFR1 signaling context for human GnRH deficiency and motivates FGF8-FGFR1 pathway modeling.
  downstream:
  - target: GnRH deficiency and hypogonadism
- name: GnRH deficiency and hypogonadism
  description: >-
    Deficiency of hypothalamic GnRH leads to inappropriately low serum gonadotropins
    (LH and FSH) and consequently low sex steroid levels. This results in absent or
    incomplete pubertal development, infertility, and decreased bone mineral density.
  biological_processes:
  - preferred_term: Gonadotropin secretion
    term:
      id: GO:0032274
      label: gonadotropin secretion
    modifier: DECREASED
  evidence:
  - reference: PMID:20301509
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Isolated gonadotropin-releasing hormone (GnRH) deficiency (IGD) is characterized by inappropriately low serum concentrations of the gonadotropins LH (luteinizing hormone) and FSH (follicle-stimulating hormone) in the presence of low circulating concentrations of sex steroids."
    explanation: Defines the core endocrine defect of IGD.
phenotypes:
- name: Delayed puberty
  description: Absent or incomplete puberty due to GnRH deficiency.
  frequency: OBLIGATE
  phenotype_term:
    preferred_term: Delayed puberty
    term:
      id: HP:0000823
      label: Delayed puberty
  evidence:
  - reference: PMID:20301509
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Adolescents and adults with IGD have clinical evidence of hypogonadism and incomplete sexual maturation on physical examination."
    explanation: Confirms delayed puberty as a cardinal feature.
- name: Anosmia
  description: Impaired sense of smell due to absent or hypoplastic olfactory bulbs, present in approximately 60% of individuals (Kallmann syndrome).
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Anosmia
    term:
      id: HP:0000458
      label: Anosmia
  evidence:
  - reference: PMID:20301509
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "IGD is associated with a normal sense of smell (normosmic IGD) in approximately 40% of affected individuals and an impaired sense of smell (Kallmann syndrome) in approximately 60%."
    explanation: Establishes anosmia frequency at approximately 60%.
- name: Micropenis
  description: Small penis in infant boys due to fetal gonadotropin deficiency.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Micropenis
    term:
      id: HP:0000054
      label: Micropenis
  evidence:
  - reference: PMID:20301509
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Infant boys with congenital IGD often have micropenis and cryptorchidism."
    explanation: Micropenis is a recognized feature in infant boys with congenital IGD.
- name: Cryptorchidism
  description: Undescended testes due to fetal gonadotropin deficiency.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Cryptorchidism
    term:
      id: HP:0000028
      label: Cryptorchidism
  evidence:
  - reference: PMID:20301509
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Infant boys with congenital IGD often have micropenis and cryptorchidism."
    explanation: Cryptorchidism is a recognized feature in infant boys with congenital IGD.
- name: Hypogonadism
  description: Low sex steroid levels with absent secondary sexual characteristics.
  frequency: OBLIGATE
  phenotype_term:
    preferred_term: Hypogonadism
    term:
      id: HP:0000135
      label: Hypogonadism
  evidence:
  - reference: PMID:20301509
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Adult males with IGD tend to have prepubertal testicular volume (i.e., <4 mL), absence of secondary sexual features (e.g., facial and axillary hair growth, deepening of the voice), decreased muscle mass, diminished libido, erectile dysfunction, and infertility."
    explanation: Describes the hypogonadal phenotype in adult males.
- name: Primary amenorrhea
  description: Absence of menstruation in affected females due to estrogen deficiency.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Primary amenorrhea
    term:
      id: HP:0000786
      label: Primary amenorrhea
  evidence:
  - reference: PMID:20301509
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Adult females have little or no breast development and primary amenorrhea."
    explanation: Confirms primary amenorrhea as a feature in affected females.
- name: Decreased bone mineral density
  description: Reduced bone mineral density due to sex steroid deficiency.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Decreased bone mineral density
    term:
      id: HP:0004349
      label: Reduced bone mineral density
  evidence:
  - reference: PMID:20301509
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Prevention of secondary complications: Optimal calcium and vitamin D intake should be encouraged and specific treatment for decreased bone mass as needed."
    explanation: Indicates decreased bone mass as a secondary complication requiring management.
- name: Infertility
  description: Inability to conceive due to absent gonadotropin-driven gametogenesis.
  frequency: OBLIGATE
  phenotype_term:
    preferred_term: Infertility
    term:
      id: HP:0000789
      label: Infertility
  evidence:
  - reference: PMID:20301509
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "diminished libido, erectile dysfunction, and infertility."
    explanation: Infertility is a core feature of IGD.
- name: Absent pubertal growth spurt
  description: Linear growth rate is usually normal but the pubertal growth spurt is absent.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Absent pubertal growth spurt
    term:
      id: HP:0001507
      label: Growth abnormality
  evidence:
  - reference: PMID:20301509
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Although skeletal maturation is delayed, the rate of linear growth is usually normal except for the absence of a distinct pubertal growth spurt."
    explanation: Describes the specific growth pattern in IGD.
- name: Orofacial cleft
  description: >-
    Cleft lip and/or cleft palate can occur as an extra-reproductive
    developmental anomaly in FGFR1-related Kallmann/normosmic IHH pedigrees.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Cleft lip and palate
    term:
      id: HP:0000202
      label: Orofacial cleft
  evidence:
  - reference: PMID:16606836
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Q680X in a nIHH male with cleft lip/palate and missing teeth, his brother with nIHH, and his father with delayed puberty."
    explanation: An FGFR1 loss-of-function family included a normosmic IHH male with cleft lip/palate and missing teeth.
  - reference: PMID:15605412
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In this study, unilateral renal agenesis and bimanual synkinesia were exclusively found associated with KAL1mutations, cleft palate and dental agenesia with FGFR1mutations."
    explanation: A KAL1/FGFR1 mutation cohort associated cleft palate with FGFR1 rather than KAL1.
- name: Tooth agenesis
  description: >-
    Missing teeth or dental agenesis is a recurrent craniofacial feature in
    FGFR1-related hypogonadotropic hypogonadism.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Tooth agenesis
    term:
      id: HP:0009804
      label: Tooth agenesis
  evidence:
  - reference: PMID:16606836
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "(P722H and N724K) in an nIHH male missing two teeth and his mother with isolated hyposmia; and (iii) Q680X in a nIHH male with cleft lip/palate and missing teeth"
    explanation: FGFR1 mutation carriers in normosmic/mixed pedigrees had missing teeth.
  - reference: PMID:15605412
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In this study, unilateral renal agenesis and bimanual synkinesia were exclusively found associated with KAL1mutations, cleft palate and dental agenesia with FGFR1mutations."
    explanation: A KAL1/FGFR1 mutation cohort associated dental agenesis with FGFR1 rather than KAL1.
- name: Oligodactyly and skeletal malformations
  description: >-
    FGFR1 loss-of-function can be associated with variable skeletal anomalies,
    including oligodactyly of the feet and metacarpal fusion, in some Kallmann
    syndrome patients.
  phenotype_term:
    preferred_term: Oligodactyly
    term:
      id: HP:0012165
      label: Oligodactyly
  evidence:
  - reference: PMID:23154428
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Three patients presented with skeletal abnormalities, i.e. spine (hemivertebra and butterfly vertebra) and limb (oligodactyly of the feet, fusion of the 4th and 5th metacarpal bones) malformations in two patients and one patient, respectively."
    explanation: This FGFR1 mutation cohort directly reports limb and spine skeletal malformations including oligodactyly.
- name: Hearing impairment
  description: >-
    Hearing loss is reported in FGF-pathway IHH cohorts that include FGFR1,
    FGF8, and FGF17 mutation carriers. This is modeled as a cautious
    FGF-pathway-associated feature rather than a proven FGFR1-only hallmark.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Hearing impairment
    term:
      id: HP:0000365
      label: Hearing impairment
  evidence:
  - reference: PMID:31748124
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "In addition to hypogonadotropic hypogonadism, 44.4% (8/18) patients exhibited other clinical deformities, including dental agenesis (3/18, 16.7%), hearing loss (3/18, 16.7%), and hand malformation (2/18, 11.1%)."
    explanation: >-
      This supports hearing loss in a combined FGFR1/FGF8/FGF17 mutation cohort,
      so the evidence is partial for FGFR1-specific attribution.
genetic:
- name: FGFR1 loss-of-function mutations
  association: Causative
  gene_term:
    preferred_term: FGFR1
    term:
      id: hgnc:3688
      label: FGFR1
  notes: >-
    Loss-of-function mutations in FGFR1 cause hypogonadotropic hypogonadism
    type 2 with or without anosmia. FGFR1 is required for GnRH neuron
    development and migration from the olfactory placode to the hypothalamus,
    and family studies show variable expressivity, incomplete penetrance, and
    occasional reversal of hypogonadotropic hypogonadism after sex-steroid
    therapy.
  evidence:
  - reference: PMID:12627230
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We establish here that loss-of-function mutations in FGFR1 underlie KAL2 whereas a gain-of-function mutation in FGFR1 has been shown to cause a form of craniosynostosis."
    explanation: This is direct evidence that FGFR1 loss-of-function mutations cause Kallmann syndrome type 2.
  - reference: PMID:16606836
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These mutations also account for some of the mixed pedigrees, thus challenging the current idea that KS and nIHH are distinct entities."
    explanation: FGFR1 mutations can underlie mixed Kallmann and normosmic IHH pedigrees.
  - reference: PMID:16764984
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A wide spectrum of reproductive function was observed among KS probands including: (1) a severe phenotype demonstrated by microphallus, cryptorchidism, no pubertal development, undetectable serum gonadotropins and low serum testosterone (T) and inhibin B; (2) partial pubertal development; (3) the fertile eunuch variant of IHH with normal testicular size and active spermatogenesis with a reversal of HH after T therapy."
    explanation: This FGFR1 cohort supports the broad reproductive severity range and possible reversal.
diagnosis:
- name: Biochemical confirmation of hypogonadotropic hypogonadism
  description: >-
    Diagnosis requires biochemical testing for low serum testosterone or
    estradiol with low or inappropriately normal LH and FSH, in the setting of
    otherwise normal anterior pituitary anatomy and function and after excluding
    secondary causes of hypogonadotropic hypogonadism.
  diagnosis_term:
    preferred_term: circulating hormone measurement
    term:
      id: MAXO:0035005
      label: circulating hormone measurement
  results: Low sex steroids with low or inappropriately normal LH and FSH support isolated GnRH deficiency.
  evidence:
  - reference: PMID:20301509
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "using biochemical testing that reveals low serum testosterone or estradiol (hypogonadism) that results from complete or partial absence of GnRH-mediated release of LH and FSH"
    explanation: GeneReviews defines the biochemical and exclusion-based diagnostic pattern for IGD.
- name: Pubertal staging and bone age assessment
  description: >-
    Children with suspected FGFR1-related IGD should receive serial pubertal
    assessment, Tanner staging, gonadotropin and sex-steroid measurements, and
    bone-age assessment after the expected age of pubertal onset.
  diagnosis_term:
    preferred_term: clinical assessment
    term:
      id: MAXO:0000487
      label: clinical assessment
  results: Absent, partial, or arrested pubertal progression with delayed bone age supports IGD over normal pubertal timing.
  evidence:
  - reference: PMID:20301509
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "For children of both sexes with findings suggestive of IGD, monitor at regular intervals after age 11 years: sexual maturation (by Tanner staging on physical examination); gonadotropin and sex hormone levels; bone age."
    explanation: GeneReviews supports serial pubertal, hormonal, and bone-age evaluation.
- name: Olfactory evaluation and pituitary or olfactory MRI
  description: >-
    Smell history or formal olfactory testing distinguishes the Kallmann branch
    from normosmic IHH. MRI is used when clinically indicated to assess olfactory
    bulbs/tracts and to confirm otherwise normal pituitary anatomy while
    excluding secondary causes.
  diagnosis_term:
    preferred_term: magnetic resonance imaging procedure
    term:
      id: MAXO:0000424
      label: magnetic resonance imaging procedure
  results: Impaired smell or olfactory-bulb abnormalities support Kallmann syndrome; normal smell and olfactory MRI support normosmic IHH.
  evidence:
  - reference: PMID:20301509
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "IGD is associated with a normal sense of smell (normosmic IGD) in approximately 40% of affected individuals and an impaired sense of smell (Kallmann syndrome) in approximately 60%."
    explanation: GeneReviews supports olfactory assessment as a core subtype distinction.
  - reference: PMID:16606836
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Heterozygous FGFR1 mutations were found in three of seven unrelated nIHH probands with normal MRI of the olfactory system"
    explanation: FGFR1-related normosmic IHH can have normal olfactory MRI.
- name: FGFR1 and multigene IGD panel testing
  description: >-
    Molecular testing should include FGFR1 and other IGD/CHH genes, with
    attention to copy-number variants and oligogenic or modifier variants because
    the phenotype overlaps Kallmann syndrome, normosmic IHH, and broader
    FGF-pathway disease.
  diagnosis_term:
    preferred_term: molecular genetic testing
    term:
      id: MAXO:0000533
      label: molecular genetic testing
  results: A pathogenic or likely pathogenic FGFR1 variant confirms FGFR1-related hypogonadotropic hypogonadism when the phenotype fits.
  evidence:
  - reference: PMID:20301509
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Pathogenic variants in more than 25 genes account for about half of all IGD; the genetic cause for the remaining cases of IGD is unknown."
    explanation: GeneReviews supports multigene testing because IGD is genetically heterogeneous.
  - reference: PMID:23643382
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Among the >15 genes implicated in these conditions, mutations in FGF8 and FGFR1 account for ~12% of cases; notably, KAL1 and HS6ST1 are also involved in FGFR1 signaling and can be mutated in CHH."
    explanation: FGF-pathway data support testing FGFR1 together with interacting CHH genes.
- name: Fertility and gonadal function evaluation
  description: >-
    Fertility evaluation should document gonadal development, gonadotropin-driven
    gametogenesis potential, reproductive goals, and counseling needs before
    selecting combined gonadotropin therapy, pulsatile GnRH therapy, or assisted
    reproduction.
  diagnosis_term:
    preferred_term: clinical assessment
    term:
      id: MAXO:0000487
      label: clinical assessment
  results: Prepubertal testicular volume, anovulation, azoospermia, or infertility guide fertility-induction planning.
  evidence:
  - reference: PMID:20301509
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Adult males with IGD tend to have prepubertal testicular volume (i.e., <4 mL), absence of secondary sexual features (e.g., facial and axillary hair growth, deepening of the voice), decreased muscle mass, diminished libido, erectile dysfunction, and infertility."
    explanation: GeneReviews supports assessing gonadal development and infertility in males.
  - reference: PMID:20301509
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "to stimulate spermatogenesis or folliculogenesis, either combined gonadotropin therapy"
    explanation: GeneReviews identifies fertility-induction options that require reproductive assessment and planning.
treatments:
- name: Testosterone or hCG therapy for male pubertal induction
  description: >-
    Gradually increasing doses of testosterone, or hCG in selected cases, induce
    and maintain male secondary sex characteristics. Testosterone alone does not
    induce spermatogenesis, so fertility planning should be addressed separately.
  treatment_term:
    preferred_term: hormone replacement therapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:20301509
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "gradually increasing doses of testosterone or human chorionic gonadotropin (hCG) injections in males or estrogen and progestin in females"
    explanation: GeneReviews describes testosterone or hCG as male pubertal induction therapy.
- name: Estrogen and progestin therapy for female pubertal induction
  description: >-
    Gradually escalating estrogen with later progestin exposure induces and
    maintains female secondary sex characteristics, supports uterine/endometrial
    health, and helps protect bone health in affected females.
  treatment_term:
    preferred_term: hormone replacement therapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:20301509
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "gradually increasing doses of testosterone or human chorionic gonadotropin (hCG) injections in males or estrogen and progestin in females"
    explanation: GeneReviews explicitly names estrogen and progestin therapy for female pubertal induction.
- name: Fertility induction with gonadotropins or pulsatile GnRH
  description: >-
    Combined gonadotropin therapy (hCG with hMG or recombinant FSH) or pulsatile
    GnRH therapy stimulates spermatogenesis or folliculogenesis when fertility is
    desired; IVF may be considered if conception fails despite gametogenesis or
    ovulation induction.
  treatment_term:
    preferred_term: gonadotropin or pulsatile GnRH fertility therapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:20301509
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "to stimulate spermatogenesis or folliculogenesis, either combined gonadotropin therapy"
    explanation: GeneReviews identifies combined gonadotropin and pulsatile GnRH therapy as fertility-induction options.
  - reference: PMID:31748124
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "hCG/hMG therapy was effective in promoting sexual development in IHH patients with FGFR1, FGF8, and FGF17 mutations."
    explanation: This mutation-positive IHH cohort supports hCG/hMG treatment response in an FGF-pathway group including FGFR1.
- name: Bone health monitoring and treatment
  description: >-
    Long-term management should include calcium and vitamin D optimization,
    monitoring bone mineral density, and treating decreased bone mass when
    present, especially after delayed diagnosis or treatment gaps.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:20301509
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Optimal calcium and vitamin D intake should be encouraged and specific treatment for decreased bone mass as needed."
    explanation: GeneReviews directly supports bone-health prevention and treatment.
  - reference: PMID:20301509
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "In individuals with confirmed IGD, monitor at regular intervals: serum sex steroid levels (to guide optimal hormone replacement); bone mineral density."
    explanation: GeneReviews supports monitoring bone mineral density in confirmed IGD.
- name: Psychosocial support and care coordination
  description: >-
    Comprehensive care should address delayed-puberty distress, body image,
    psychosexual development, adherence, transition to adult endocrine care, peer
    support, and referral for mental health services when needed.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:31333578
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "This review provides a summary of the psychological aspects of CHH/KS and outlines an approach to comprehensive care that spans medical management as well as appropriate attention, care and referrals to peer-to-peer support and mental health services to ameliorate the psychological aspects of CHH/KS."
    explanation: This CHH/Kallmann review supports explicit psychosocial and mental-health support in care planning.
- name: Genetic and reproductive counseling
  description: >-
    Counseling should cover autosomal dominant inheritance with incomplete
    penetrance, variable expressivity, de novo occurrence, oligogenic/modifier
    variants, recurrence risk based on family history and molecular results, and
    the possibility of transmitting FGFR1 or FGF-pathway variants after
    successful fertility treatment.
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
  evidence:
  - reference: PMID:20301509
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Almost all IGD-related genes have also been associated with indeterminate or oligogenic inheritance. Recurrence risk counseling is based on family history and the results of molecular genetic testing when available."
    explanation: GeneReviews supports counseling around oligogenic inheritance and recurrence risk.
  - reference: PMID:31748124
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "hCG/hMG therapy was effective to acquire fertility for patients with FGFR1, FGF8, and FGF17 mutations but has a risk of transmitting the mutations and IHH to the next generation."
    explanation: This supports reproductive counseling after fertility induction in FGF-pathway mutation carriers.
references:
- reference: PMID:20301509
  title: "Isolated Gonadotropin-Releasing Hormone (GnRH) Deficiency."
  tags:
  - GeneReviews
  findings: []
- reference: PMID:12627230
  title: Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome.
  findings: []
- reference: PMID:16606836
  title: Mutations in fibroblast growth factor receptor 1 cause both Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism.
  findings: []
- reference: PMID:16764984
  title: Mutations in fibroblast growth factor receptor 1 cause Kallmann syndrome with a wide spectrum of reproductive phenotypes.
  findings: []
- reference: PMID:17235395
  title: Digenic mutations account for variable phenotypes in idiopathic hypogonadotropic hypogonadism.
  findings: []
- reference: PMID:18596921
  title: Decreased FGF8 signaling causes deficiency of gonadotropin-releasing hormone in humans and mice.
  findings: []
- reference: PMID:18985070
  title: Kallmann syndrome.
  findings: []
- reference: PMID:23154428
  title: Evidence that FGFR1 loss-of-function mutations may cause variable skeletal malformations in patients with Kallmann syndrome.
  findings: []
- reference: PMID:23643382
  title: "Mutations in FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 are identified in individuals with congenital hypogonadotropic hypogonadism."
  findings: []
- reference: PMID:31333578
  title: Psychological Aspects of Congenital Hypogonadotropic Hypogonadism.
  findings: []
- reference: PMID:31748124
  title: "Genotypic and phenotypic spectra of FGFR1, FGF8, and FGF17 mutations in a Chinese cohort with idiopathic hypogonadotropic hypogonadism."
  findings: []
notes: >-
  Bimanual synkinesia is not modeled as an FGFR1 phenotype here because the
  verified KAL1/FGFR1 cohort evidence found it exclusively with KAL1 mutations,
  while cleft palate and dental agenesis tracked with FGFR1 mutations. Hearing
  impairment is included with partial support because the available cached
  evidence is from a combined FGFR1/FGF8/FGF17 mutation cohort rather than a
  clean FGFR1-only series.
📚

References & Deep Research

References

11
PMID:20301509
Isolated Gonadotropin-Releasing Hormone (GnRH) Deficiency.
No top-level findings curated for this source.
PMID:12627230
Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome.
No top-level findings curated for this source.
PMID:16606836
Mutations in fibroblast growth factor receptor 1 cause both Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism.
No top-level findings curated for this source.
PMID:16764984
Mutations in fibroblast growth factor receptor 1 cause Kallmann syndrome with a wide spectrum of reproductive phenotypes.
No top-level findings curated for this source.
PMID:17235395
Digenic mutations account for variable phenotypes in idiopathic hypogonadotropic hypogonadism.
No top-level findings curated for this source.
PMID:18596921
Decreased FGF8 signaling causes deficiency of gonadotropin-releasing hormone in humans and mice.
No top-level findings curated for this source.
PMID:18985070
Kallmann syndrome.
No top-level findings curated for this source.
PMID:23154428
Evidence that FGFR1 loss-of-function mutations may cause variable skeletal malformations in patients with Kallmann syndrome.
No top-level findings curated for this source.
PMID:23643382
Mutations in FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 are identified in individuals with congenital hypogonadotropic hypogonadism.
No top-level findings curated for this source.
PMID:31333578
Psychological Aspects of Congenital Hypogonadotropic Hypogonadism.
No top-level findings curated for this source.
PMID:31748124
Genotypic and phenotypic spectra of FGFR1, FGF8, and FGF17 mutations in a Chinese cohort with idiopathic hypogonadotropic hypogonadism.
No top-level findings curated for this source.

Deep Research

1
Falcon ▸
FGFR1-Related Hypogonadotropic Hypogonadism (FGFR1-related CHH/KS): Comprehensive Disease Characteristics Report
Edison Scientific Literature 39 citations 2026-04-04T12:38:05.111257

FGFR1-Related Hypogonadotropic Hypogonadism (FGFR1-related CHH/KS): Comprehensive Disease Characteristics Report

Scope note. “FGFR1-related hypogonadotropic hypogonadism” is commonly used clinically to denote hypogonadotropic hypogonadism 2 with or without anosmia, i.e., congenital/idiopathic GnRH deficiency due to pathogenic FGFR1 variants spanning Kallmann syndrome (KS; with hypo/anosmia) and normosmic CHH/IHH. The evidence base below comes from aggregated cohort studies and curated diagnostic resources plus individual case reports; where cohort-level statistics are provided, they are explicitly identified.

1. Disease Information

1.1 Concise overview

FGFR1-related CHH/KS is a Mendelian developmental disorder of the reproductive neuroendocrine axis caused by impaired FGFR1-mediated signaling during development, leading to deficient GnRH neuron development and/or function. Clinically it presents as absent or incomplete puberty, low sex steroids with low/inappropriately normal LH/FSH, and infertility; in the KS subtype, it is accompanied by anosmia/hyposmia and often olfactory bulb/tract hypoplasia/aplasia. Non-reproductive anomalies (e.g., dental agenesis, cleft lip/palate, synkinesia, hearing loss, renal and skeletal anomalies) occur due to broad roles of FGFR1 in embryonic patterning. (chu2023mutationspectrumof pages 1-2, dode2003lossoffunctionmutationsin pages 1-2, chung2023theinitiationand pages 2-3)

1.2 Key identifiers (ontology and genetic)

A harmonized identifier/synonym table is provided here:

Entity name Related disease labels / synonyms MONDO ID OMIM / MIM IDs mentioned in retrieved sources Notes on scope and source
FGFR1-related hypogonadotropic hypogonadism FGFR1-related CHH; FGFR1-related IHH; FGFR1-related Kallmann syndrome spectrum MONDO_0007844 FGFR1 gene: OMIM 136350; IHH: MIM 147950 FGFR1 is the canonical causal gene for “hypogonadotropic hypogonadism 2 with or without anosmia,” spanning anosmic and normosmic presentations; gene-disease pairing supported by Open Targets/MONDO and primary literature (xu2023howhumangenetic pages 1-2, dode2003lossoffunctionmutationsin pages 1-2)
Hypogonadotropic hypogonadism 2 with or without anosmia KS2; FGFR1-related HH; FGFR1-related CHH with or without anosmia MONDO_0007844 FGFR1 gene: OMIM 136350 Most disease-specific MONDO label linked to FGFR1 in Open Targets evidence; corresponds to autosomal dominant FGFR1-associated disease first established by Dodé et al. (dode2003lossoffunctionmutationsin pages 1-2)
Congenital hypogonadotropic hypogonadism CHH; congenital GnRH deficiency; isolated GnRH deficiency MONDO_0015770 IHH/CHH commonly discussed under MIM 147950 in retrieved sources Higher-level disease category including FGFR1-related cases; used in recent diagnostic/genetic reviews and panel-testing discussions (vezzoli2023geneticarchitectureof pages 3-5, sayed2023paneltestingfor pages 2-3)
Hypogonadotropic hypogonadism HH; hypogonadotropic hypogonadism spectrum MONDO_0018555 Not disease-specific in retrieved FGFR1 papers Broad umbrella term from Open Targets/MONDO; useful for database harmonization but less specific than CHH/KS labels (sayed2023paneltestingfor pages 2-3)
Kallmann syndrome KS; IHH with anosmia; anosmic CHH No MONDO ID retrieved in provided Open Targets context OMIM series listed in Men et al.: 308700, 147950, 244200, 610628, 612370, 612702 Clinical subtype defined by hypogonadotropic hypogonadism plus anosmia/hyposmia; Men et al. note ~60% of IHH cases are associated with anosmia and provide a KS OMIM list reflecting locus heterogeneity rather than a single FGFR1-specific identifier (men2020genotypicandphenotypic pages 1-2, chu2023mutationspectrumof pages 1-2)
Idiopathic hypogonadotropic hypogonadism IHH; isolated hypogonadotropic hypogonadism; normosmic IHH when smell is normal No MONDO ID retrieved in provided Open Targets context for the exact term IHH: MIM 147950; Men et al. also cite 612370 in the IHH/KS context Literature term widely used in FGFR1 studies, especially older and cohort papers; includes both normosmic and anosmic forms depending on olfactory status (men2020genotypicandphenotypic pages 1-2, xu2023howhumangenetic pages 1-2, goncalves2015novelfgfr1mutations pages 1-2)
Normosmic idiopathic hypogonadotropic hypogonadism nIHH; normosmic CHH Not retrieved in provided Open Targets context Usually discussed under IHH MIM 147950 in retrieved sources Important phenotypic label because FGFR1 variants can cause both KS and normosmic IHH; emphasizes variable expressivity within the same gene (dode2003lossoffunctionmutationsin pages 1-2, goncalves2015novelfgfr1mutations pages 1-2)

Table: This table organizes the key disease labels, MONDO identifiers, OMIM/MIM references, and common synonyms relevant to FGFR1-related hypogonadotropic hypogonadism and the Kallmann syndrome spectrum. It is useful for harmonizing database entries with the terminology used in both recent literature and disease ontologies.

MONDO IDs available from Open Targets evidence include: - Hypogonadotropic hypogonadism: MONDO_0018555 (sayed2023paneltestingfor pages 2-3) - Congenital hypogonadotropic hypogonadism: MONDO_0015770 (sayed2023paneltestingfor pages 2-3) - Hypogonadotropic hypogonadism 2 with or without anosmia (FGFR1-related): MONDO_0007844 (sayed2023paneltestingfor pages 2-3)

OMIM/MIM IDs available in retrieved primary literature include: - FGFR1 gene: OMIM 136350 (men2020genotypicandphenotypic pages 1-2, dode2003lossoffunctionmutationsin pages 1-2) - Idiopathic hypogonadotropic hypogonadism (IHH): MIM 147950 (xu2023howhumangenetic pages 1-2) - Men et al. list multiple OMIM entries for KS locus heterogeneity (e.g., 308700, 147950, 244200, 610628, 612370, 612702) (men2020genotypicandphenotypic pages 1-2).

Gaps. ICD-10/ICD-11, MeSH, and Orphanet identifiers were not present in the full-texts retrieved via the current tool runs; therefore they are not asserted here.

1.3 Synonyms and alternative names

Common labels include: - Kallmann syndrome (KS) (IHH/CHH with hypo/anosmia) (chu2023mutationspectrumof pages 1-2) - Congenital hypogonadotropic hypogonadism (CHH) (with or without anosmia) (dwyer2024classesandpredictors pages 3-4) - Idiopathic hypogonadotropic hypogonadism (IHH), including normosmic IHH (xu2023howhumangenetic pages 1-2, goncalves2015novelfgfr1mutations pages 1-2)

1.4 Evidence provenance (individual vs aggregated)

  • Aggregated disease-level resources: UK NHSE/PanelApp curated gene panels and gene-disease assertions informing clinical testing pipelines (sayed2023paneltestingfor pages 2-3).
  • Human cohort studies: e.g., Chinese IHH cohort genotype/phenotype analyses (men2020genotypicandphenotypic pages 1-2).
  • Case reports: e.g., females with primary amenorrhea and KS due to de novo FGFR1 variants (xia2021twofemalespresenting pages 1-2).

2. Etiology

2.1 Primary causal factors

Genetic cause (primary). Pathogenic variants in FGFR1 cause autosomal dominant CHH/KS (historically “KAL2”), first established by Dodé et al. in 2003 as “Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome.” (Nature Genetics; Mar 2003; https://doi.org/10.1038/ng1122) (dode2003lossoffunctionmutationsin pages 1-2).

Mechanistic cause (developmental). FGFR1 participates in FGF signaling required for development of GnRH neurons and olfactory structures; reduced dosage/signaling disrupts these developmental processes, producing GnRH deficiency with or without anosmia. (chung2023theinitiationand pages 2-3, dode2003lossoffunctionmutationsin pages 1-2)

2.2 Risk factors

  • Genetic: heterozygous FGFR1 pathogenic variants (missense/nonsense/splice/indels) and, in some families, CNVs involving chromosome 8p/FGFR1 locus; Chu et al. reported a pathogenic del(8)(p12p11.22) CNV in a KS family and a frameshift FGFR1 variant (RB&E; Mar 2023; https://doi.org/10.1186/s12958-023-01074-w) (chu2023mutationspectrumof pages 1-2).
  • Oligogenicity as risk/complexity: FGFR1 variants can be part of di-/oligogenic inheritance and may interact with variants in other CHH genes; oligogenicity complicates penetrance and expressivity (goncalves2015novelfgfr1mutations pages 3-4, sayed2023paneltestingfor pages 2-3).

Environmental risk factors. No specific toxin/lifestyle triggers were identified in the retrieved FGFR1-focused texts. CHH in general can show variable penetrance and may be influenced by non-genetic factors, but FGFR1-specific gene–environment interactions were not evidenced in the provided sources. (pitteloud2010complexgeneticsin pages 9-10, vezzoli2023geneticarchitectureof pages 3-5)

2.3 Protective factors

FGFR1-specific protective factors (genetic or environmental) were not identified in the retrieved sources.

2.4 Gene–environment interactions

No FGFR1-specific G×E evidence was retrieved.

3. Phenotypes

A phenotype-to-HPO mapping table (with onset/course and frequency notes where available) is provided below:

Phenotype (plain language) Suggested HPO term(s) and IDs Typical onset/course Frequency notes (if in evidence) Supporting citation IDs from provided context
Absent or incomplete puberty / hypogonadotropic hypogonadism Hypogonadotropic hypogonadism (HP:0000044); Delayed puberty (HP:0000823); Absent puberty (HP:0008194) Congenital disorder usually recognized in adolescence because of absent/incomplete pubertal development; chronic lifelong course in most patients, though reversal can occur KS accounts for ~50% of IHH; CHH reversal reported in ~10–15% of cases; reversible CHH broader literature 5–20% (chu2023mutationspectrumof pages 1-2, dwyer2024classesandpredictors pages 3-4, vezzoli2023geneticarchitectureof pages 3-5)
Anosmia or hyposmia Anosmia (HP:0000458); Hyposmia (HP:0004409) Congenital/early-onset olfactory deficit; usually stable About half of IHH/CHH cases are KS with hypo/anosmia; Men 2020 notes ~60% of IHH associated with anosmia (men2020genotypicandphenotypic pages 1-2, chu2023mutationspectrumof pages 1-2)
Olfactory bulb/tract aplasia or hypoplasia on MRI Aplasia/Hypoplasia of the olfactory bulb (suggested HPO: Olfactory bulb aplasia/hypoplasia, if available in implementation set); Abnormality of the olfactory lobe (HP:0009914) Congenital structural anomaly, typically stable on imaging MRI evidence used in diagnosis; Xia 2021 described dysplastic or absent olfactory bulbs and tracts in affected females (dode2003lossoffunctionmutationsin pages 1-2)
Delayed puberty in relatives / variable expressivity Delayed puberty (HP:0000823) Adolescence; may be milder than proband phenotype Seen in FGFR1 families with intrafamilial variability and incomplete penetrance (xu2023howhumangenetic pages 1-2, goncalves2015novelfgfr1mutations pages 3-4, dode2003lossoffunctionmutationsin pages 1-2)
Micropenis and/or cryptorchidism in severe male cases Micropenis (HP:0000054); Cryptorchidism (HP:0000028) Congenital/infancy markers of severe GnRH deficiency; may precede pubertal failure Not quantified in retrieved FGFR1-specific excerpts here, but included in severe CHH phenotype descriptions and reversal stratification work (dwyer2024classesandpredictors pages 3-4, dwyer2024classesandpredictors pages 9-11)
Dental agenesis Tooth agenesis (HP:0009804) Congenital developmental anomaly; permanent Extra-reproductive anomaly repeatedly reported in FGFR1 cohorts; 44.4% of mutation-positive patients in Men 2020 had extra-reproductive anomalies including dental agenesis (men2020genotypicandphenotypic pages 1-2, chu2023mutationspectrumof pages 1-2, dode2003lossoffunctionmutationsin pages 1-2)
Cleft lip and/or cleft palate Cleft upper lip (HP:0000204); Cleft palate (HP:0000175) Congenital; fixed structural anomaly Included among recurrent non-reproductive FGFR1-associated anomalies (chu2023mutationspectrumof pages 1-2, dode2003lossoffunctionmutationsin pages 1-2)
Bimanual synkinesis / mirror movements Mirror movements (HP:0001039); Synkinesia (HP:0001334) Congenital/childhood, usually persistent Classic associated anomaly in FGFR1/KS spectrum (chu2023mutationspectrumof pages 1-2, dode2003lossoffunctionmutationsin pages 1-2)
Corpus callosum agenesis Agenesis of corpus callosum (HP:0001274) Congenital brain malformation; static structural feature Reported among associated anomalies in FGFR1 mutation carriers (dode2003lossoffunctionmutationsin pages 1-2)
Hearing loss / hearing impairment Hearing impairment (HP:0000365); Sensorineural hearing impairment (HP:0000407) Congenital or early-onset; variable severity Men 2020: hearing loss occurred in 5% of IHH individuals; one cited cohort found 16% (7/43) of KS patients with FGFR1/FGF8 mutations had hearing loss (men2020genotypicandphenotypic pages 5-8, men2020genotypicandphenotypic pages 1-2, dode2003lossoffunctionmutationsin pages 1-2)
Renal agenesis or renal hypoplasia Renal agenesis (HP:0000122); Renal hypoplasia (HP:0000089) Congenital structural anomaly Listed as associated non-reproductive feature in KS/FGFR1 spectrum; no percentage in retrieved excerpts (chu2023mutationspectrumof pages 1-2)
Skeletal/limb anomalies (syndactyly, oligodactyly, clinodactyly, hand malformations) Syndactyly (HP:0001159); Oligodactyly (HP:0001180); Clinodactyly of the 5th finger (HP:0004209); Split hand (HP:0001177) / Split foot (HP:0001839) where relevant Congenital developmental anomalies Men 2020 reported hand malformations among extra-reproductive anomalies; Chu 2023 lists skeletal anomalies broadly (men2020genotypicandphenotypic pages 5-8, men2020genotypicandphenotypic pages 1-2, chu2023mutationspectrumof pages 1-2)
Gonadal dysplasia / primary amenorrhea in females Primary amenorrhea (HP:0000043); Hypogonadism (HP:0000135) Usually adolescence; chronic unless treated Xia 2021 described females presenting primary amenorrhea without puberty due to FGFR1 variants (dode2003lossoffunctionmutationsin pages 1-2)
Potential spontaneous reversal of reproductive axis dysfunction No exact HPO disease-course term; suggest annotation as clinical course note rather than phenotype Usually early adulthood after years of treatment; may relapse, so requires monitoring Dwyer 2024: spontaneous reversal in ~10–15% of CHH cases; broader review range 5–20% (dwyer2024classesandpredictors pages 3-4, vezzoli2023geneticarchitectureof pages 3-5)

Table: This table maps key clinical features of FGFR1-related hypogonadotropic hypogonadism/Kallmann syndrome to suggested HPO terms, with onset/course and frequency notes where available. It is designed to support knowledge-base phenotype annotation grounded in the cited evidence.

3.1 Key phenotype themes (narrative)

  • Core reproductive phenotype: absent/incomplete puberty with low sex steroids and low/inappropriately normal LH/FSH (CHH/IHH). (dwyer2024classesandpredictors pages 3-4)
  • Olfactory phenotype: anosmia/hyposmia; MRI may show absent/hypoplastic olfactory bulbs and tracts. Xia et al. report: “Magnetic resonance imaging showed dysplastic or absent olfactory bulbs and tracts.” (J Obstet Gynaecol Res; Aug 2021; https://doi.org/10.1111/jog.14966) (xia2021twofemalespresenting pages 1-2).
  • Extra-reproductive anomalies: cleft lip/palate, dental agenesis, synkinesia, corpus callosum agenesis, hearing loss, renal and skeletal anomalies. These were described in early FGFR1 discovery work and reiterated in later cohort literature. (dode2003lossoffunctionmutationsin pages 1-2, men2020genotypicandphenotypic pages 5-8, chu2023mutationspectrumof pages 1-2)

3.2 Quantitative phenotype data (recently extracted)

  • In a Chinese IHH cohort study, 44.4% of mutation-positive individuals (FGFR1/FGF8/FGF17) had extra-reproductive anomalies (including dental agenesis, hearing loss, and hand malformations) (Fertility & Sterility; Jan 2020; https://doi.org/10.1016/j.fertnstert.2019.08.069) (men2020genotypicandphenotypic pages 1-2).
  • Hearing loss frequency reported in the same context: “Hearing loss occurred in 5% of IHH individuals,” and a cited cohort found 16% (7/43) of KS patients with FGFR1/FGF8 mutations had hearing loss (men2020genotypicandphenotypic pages 5-8).

4. Genetic / Molecular Information

4.1 Causal gene

  • FGFR1 (fibroblast growth factor receptor 1; OMIM 136350) is the canonical causal gene for hypogonadotropic hypogonadism 2 with or without anosmia (dode2003lossoffunctionmutationsin pages 1-2).

4.2 Pathogenic variant spectrum and classification

Variant classes (germline). Across studies, pathogenic FGFR1 variants include missense, nonsense, splice-site, and small indels, and larger CNVs affecting the locus. Dodé et al. enumerated multiple heterozygous variants across receptor domains in the seminal report (dode2003lossoffunctionmutationsin pages 1-2). Chu et al. (2023) state that “>300 FGFR1 mutations (missense, nonsense, splice, rare deletions) are reported in HGMD” and report both an FGFR1 frameshift and an 8p deletion CNV (chu2023mutationspectrumof pages 1-2).

Functional consequences. - Many disease-causing variants reduce receptor function (loss-of-function/haploinsufficiency), consistent with autosomal dominant disease (dode2003lossoffunctionmutationsin pages 1-2). - Some truncating variants can remove transmembrane/intracellular domains; Men et al. describe truncating receptors “without the transmembrane and intracellular domains” and report an FGFR1 variant (p.W289X) with a “dominant negative effect by interfering with the function of wild-type receptor” (men2020genotypicandphenotypic pages 5-8).

Incomplete penetrance and variable expressivity. - Gonçalves et al. report FGFR1 mutations “inherited from an apparently normal parent,” described as “cases of incomplete penetrance,” and identify a trigenic mutation in one case supporting oligogenicity (Fertility & Sterility; Nov 2015; https://doi.org/10.1016/j.fertnstert.2015.07.1142) (goncalves2015novelfgfr1mutations pages 3-4). - Dodé et al. likewise reported unaffected carriers and variable expressivity among relatives (dode2003lossoffunctionmutationsin pages 1-2).

4.3 2023 methodological advance: FGFR1 variant interpretation using human genetic context

Xu et al. (Human Genetics; Oct 2023; https://doi.org/10.1007/s00439-023-02601-w) analyze 143 FGFR1 rare sequence variants in 175 IHH probands (95 missense; 48 protein-truncating) and show that FGFR1 missense variants are regionally enriched in functional domains. Incorporating this enrichment into ACMG/AMP evidence reclassified 37% (20/54) of FGFR1 missense VUS to pathogenic/likely pathogenic, and phenotypic enrichment among non-proband carriers supported the reclassification (xu2023howhumangenetic pages 1-2).

4.4 Modifier genes / oligogenicity

Oligogenic inheritance is documented in FGFR1-related IHH/KS families (e.g., co-occurring variants in other CHH genes), complicating classical Mendelian counseling (goncalves2015novelfgfr1mutations pages 3-4, goncalves2015novelfgfr1mutations pages 1-2). Recent clinical genetics reviews emphasize that di-/oligogenic inheritance and incomplete penetrance are key interpretive challenges in CHH (sayed2023paneltestingfor pages 2-3).

4.5 Epigenetics / chromosomal abnormalities

No FGFR1-specific epigenetic mechanism evidence was retrieved. Large structural variants affecting the FGFR1 region are relevant (e.g., 8p deletion CNV reported as pathogenic) (chu2023mutationspectrumof pages 1-2).

5. Environmental Information

No FGFR1-specific environmental contributors (toxins, lifestyle, infections) were identified in the retrieved sources. The disease is best supported as a neurodevelopmental genetic disorder with variable expressivity and penetrance (dode2003lossoffunctionmutationsin pages 1-2, sayed2023paneltestingfor pages 2-3).

6. Mechanism / Pathophysiology

6.1 Causal chain (from gene to clinical phenotype)

  1. Upstream trigger: germline FGFR1 loss-of-function (or signaling impairment) (dode2003lossoffunctionmutationsin pages 1-2).
  2. Developmental effect: reduced FGF8→FGFR1 signaling compromises GnRH neuron neurogenesis/progenitor survival/differentiation in the olfactory placode neurogenic niche (chung2023theinitiationand pages 2-3, chung2023theinitiationand pages 6-6).
  3. Anatomical effect: impairment in olfactory placode/olfactory bulb development (explaining anosmia/hyposmia in KS) and disruption of the GnRH neuron migratory route to the hypothalamus (chung2023theinitiationand pages 2-3, dode2003lossoffunctionmutationsin pages 1-2).
  4. Physiologic effect: reduced hypothalamic GnRH drive → low/inappropriately normal LH/FSH → low sex steroids (hypogonadotropic hypogonadism) (dwyer2024classesandpredictors pages 3-4).
  5. Clinical outcome: absent/incomplete puberty, infertility; in KS, anosmia/hyposmia and olfactory bulb/tract hypoplasia/aplasia; plus extra-reproductive congenital anomalies due to broader FGFR1 developmental roles (chu2023mutationspectrumof pages 1-2, dode2003lossoffunctionmutationsin pages 1-2).

6.2 Pathway-level summary with ontology suggestions

A structured mechanism table with suggested GO/CL/UBERON annotations is provided:

Level Mechanism statement Key genes/proteins Pathway annotations Suggested GO Biological Process terms Suggested CL cell types Suggested UBERON anatomical structures Evidence type Supporting citation IDs
Molecular FGFR1 loss-of-function is a primary upstream mechanism in FGFR1-related CHH/KS; pathogenic variants include missense, nonsense, splice-site, indels, and CNVs, reducing receptor dosage or signaling capacity. Some variants may also impair receptor dimerization or act dominant-negatively. FGFR1 FGF receptor signaling pathway; receptor tyrosine kinase signaling; MAPK/ERK signaling GO:0008543 fibroblast growth factor receptor signaling pathway; GO:0007169 transmembrane receptor protein tyrosine kinase signaling pathway; GO:0000165 MAPK cascade CL:0000540 neuron UBERON:0000955 brain; UBERON:0001898 olfactory bulb Human genetics (chu2023mutationspectrumof pages 1-2, dode2003lossoffunctionmutationsin pages 1-2, men2020genotypicandphenotypic pages 1-2)
Molecular FGF8 is a key ligand for FGFR1 during GnRH neuron ontogeny; reduced FGF8-FGFR1 signaling decreases emergence of GnRH neurons and contributes to GnRH deficiency. FGF8, FGFR1 FGF signaling; ligand-receptor activation; MAPK/ERK GO:0008543 fibroblast growth factor receptor signaling pathway; GO:0022008 neurogenesis; GO:0045664 regulation of neuron differentiation CL:0000540 neuron; CL:0000039 germ line hormone-releasing hormone neuron UBERON:0002430 olfactory placode; UBERON:0001137 hypothalamus Human genetics, mouse model (chung2023theinitiationand pages 2-3, chung2023theinitiationand pages 6-6, miraoui2013mutationsinfgf17 pages 3-3)
Molecular ANOS1/anosmin-1 modulates FGFR1 signaling through interaction with the FGF-FGFR-heparan sulfate complex; HSPGs facilitate FGF-FGFR complex dimerization, linking extracellular matrix biology to receptor activation. ANOS1, FGFR1, HSPGs, FGF ligands FGF signaling; heparan sulfate proteoglycan-dependent signaling; extracellular matrix modulation GO:0008543 fibroblast growth factor receptor signaling pathway; GO:0006027 glycosaminoglycan catabolic process (broader HSPG context); GO:0030200 heparan sulfate proteoglycan metabolic process CL:0000540 neuron UBERON:0000955 brain; UBERON:0002430 olfactory placode Human genetics, mechanistic model (men2020genotypicandphenotypic pages 5-8, dode2003lossoffunctionmutationsin pages 1-2)
Molecular FGFR1 protein architecture is mechanistically relevant: ligand-binding determinants localize to D2/D3 and the linker, while alternative splicing generates FGFR1b and FGFR1c isoforms with distinct ligand specificities; pathogenic variants in these domains alter ligand recognition and downstream signaling. FGFR1, FGF8 FGF receptor binding specificity; receptor isoform-dependent signaling GO:0005007 fibroblast growth factor-activated receptor activity; GO:0007169 transmembrane receptor protein tyrosine kinase signaling pathway CL:0000540 neuron UBERON:0002430 olfactory placode Human genetics, in silico structural interpretation (men2020genotypicandphenotypic pages 1-2, goncalves2015novelfgfr1mutations pages 1-2)
Cellular Fgfr1/Fgf8 deficiency acts upstream of GnRH neuron birth: homozygous Fgf8 hypomorph mice show complete loss of GnRH neurons by E11.5, while Fgfr1 hypomorphic newborns show about 90% reduction, indicating a requirement for progenitor survival and neuronal differentiation. FGF8, FGFR1 Developmental FGF signaling; neuronal differentiation; survival signaling GO:0022008 neurogenesis; GO:0030154 cell differentiation; GO:0043523 regulation of neuron apoptotic process CL:0000039 germ line hormone-releasing hormone neuron; CL:0000540 neuron UBERON:0002430 olfactory placode; UBERON:0001137 hypothalamus Mouse model (chung2023theinitiationand pages 2-3, chung2023theinitiationand pages 6-6, chung2023theinitiationand media 627f77bc)
Cellular GnRH neurons originate outside the CNS in the medial ventral olfactory placode and then migrate along olfactory/vomeronasal/terminal nerve fibers through the cribriform plate toward the preoptic area and hypothalamus; disrupted FGFR1 signaling compromises this developmental trajectory. FGFR1, FGF8 Neuronal migration; axon guidance; developmental patterning GO:0001764 neuron migration; GO:0007411 axon guidance; GO:0021795 cerebral cortex cell migration (broader neurodevelopment context) CL:0000039 germ line hormone-releasing hormone neuron; CL:0000540 neuron UBERON:0002430 olfactory placode; UBERON:0008933 cribriform plate; UBERON:0001137 hypothalamus; UBERON:0001871 preoptic area Mouse model, developmental neurobiology (chung2023theinitiationand pages 2-3, chung2023theinitiationand pages 6-6, chung2023theinitiationand media 627f77bc)
Cellular FGFR1 also interfaces with axonal morphogenesis pathways: in C. elegans, kal1 mis/overexpression produces an axon-branching phenotype abolished by defects in heparan-sulfate sulfation, supporting a conserved requirement for anosmin/HSPG-dependent morphogenesis. KAL1/ANOS1 ortholog, HSPGs, FGFR-related signaling context Axon branching; extracellular matrix-guided morphogenesis GO:0007416 synapse assembly (broader neuronal wiring context); GO:0031175 neuron projection development; GO:0007411 axon guidance CL:0000540 neuron UBERON-equivalent not applicable across species; human-relevant mapping: UBERON:0000955 brain C. elegans model (dode2003lossoffunctionmutationsin pages 1-2)
Anatomical Olfactory bulb development is dosage-sensitive to FGFR1 signaling in humans; reduced FGFR1 dosage contributes to olfactory bulb aplasia/hypoplasia, a structural correlate of anosmia/hyposmia in KS. FGFR1 FGF signaling in forebrain/olfactory development GO:0048856 anatomical structure development; GO:0022008 neurogenesis; GO:0001755 neural crest cell migration (broader craniofacial context) CL:0000540 neuron; CL:0000679 olfactory receptor neuron UBERON:0001898 olfactory bulb; UBERON:0002430 olfactory placode; UBERON:0000948 forebrain Human genetics (dode2003lossoffunctionmutationsin pages 1-2, xia2021twofemalespresenting pages 2-5)
Anatomical FGF pathway expression in the embryonic olfactory placode links early nasal/olfactory development to later hypothalamic reproductive function; Miraoui et al. identify FGF-family expression in the olfactory placode and mouse knockout phenotypes affecting craniofacial/olfactory structures. FGF17, FGF8, FGFR1 FGF signaling in embryonic patterning GO:0009790 embryo development; GO:0048856 anatomical structure development; GO:0060325 face morphogenesis CL:0000540 neuron UBERON:0002430 olfactory placode; UBERON:0001898 olfactory bulb; UBERON:0000167 nose Human genetics, mouse model (miraoui2013mutationsinfgf17 pages 3-3)
Clinical The downstream clinical syndrome reflects failed GnRH neuronal development and/or migration: absent or incomplete puberty, hypogonadotropic hypogonadism, infertility, and anosmia/hyposmia; MRI may show dysplastic or absent olfactory bulbs and tracts. FGFR1, FGF8 Hypothalamic-pituitary-gonadal axis dysfunction secondary to developmental neuroendocrine defect GO:0003006 developmental process involved in reproduction; GO:0007399 nervous system development CL:0000039 germ line hormone-releasing hormone neuron; CL:0000151 pituitary gonadotroph UBERON:0001137 hypothalamus; UBERON:0000007 pituitary gland; UBERON:0001898 olfactory bulb Human clinical genetics (chu2023mutationspectrumof pages 1-2, xia2021twofemalespresenting pages 2-5, xia2021twofemalespresenting pages 1-2)
Clinical Extra-gonadal anomalies arise because FGFR1 signaling contributes broadly to embryonic patterning beyond the reproductive axis; reported features include dental agenesis, cleft lip/palate, hearing loss, renal anomalies, and digital/limb malformations. FGFR1, FGF8 Developmental patterning; craniofacial and limb morphogenesis GO:0060325 face morphogenesis; GO:0035108 limb morphogenesis; GO:0001501 skeletal system development CL:0000066 epithelial cell; CL:0000540 neuron UBERON:0000164 mouth; UBERON:0002371 kidney; UBERON:0002101 limb Human genetics (men2020genotypicandphenotypic pages 5-8, men2020genotypicandphenotypic pages 1-2, chu2023mutationspectrumof pages 1-2, dode2003lossoffunctionmutationsin pages 1-2)

Table: This table summarizes the multilevel pathophysiology of FGFR1-related congenital hypogonadotropic hypogonadism/Kallmann syndrome, linking molecular defects in FGF signaling to GnRH neuron development, olfactory anatomy, and clinical features. It also proposes ontology annotations useful for knowledge-base curation.

6.3 Model-organism evidence (key quantitative results)

Chung & Tsai (Frontiers in Endocrinology; Apr 2023; https://doi.org/10.3389/fendo.2023.1166132) summarize strong mouse evidence for FGF signaling upstream of GnRH neuron birth: - Homozygous Fgf8 hypomorphic mice: complete loss of GnRH neurons by E11.5 - Fgfr1 hypomorphic newborn mice: ~90% reduction in GnRH neurons - Heterozygous Fgf8 hypomorphs: ~50% loss (chung2023theinitiationand pages 2-3)

A schematic depiction of the GnRH developmental trajectory and the role of Fgf8/Fgfr1 is available in the retrieved figure (chung2023theinitiationand media 627f77bc).

7. Anatomical Structures Affected

Primary systems: neuroendocrine (hypothalamic–pituitary–gonadal axis) and olfactory system. (chung2023theinitiationand pages 2-3, dwyer2024classesandpredictors pages 3-4)

Key anatomical structures (UBERON suggestions): - Olfactory placode (origin of GnRH neurons in development) (chung2023theinitiationand pages 2-3) - Cribriform plate (migration corridor) (chung2023theinitiationand pages 2-3) - Preoptic area and hypothalamus (final GnRH neuron destinations) (chung2023theinitiationand pages 2-3) - Median eminence (GnRH neurosecretory target site) (chung2023theinitiationand pages 2-3) - Olfactory bulbs/tracts (structural substrate for anosmia; often hypoplastic/aplastic on MRI) (xia2021twofemalespresenting pages 1-2)

Secondary structures (developmental anomalies): craniofacial structures (clefting), teeth (dental agenesis), kidneys (renal anomalies), limbs/digits (skeletal malformations), auditory apparatus (hearing loss). (chu2023mutationspectrumof pages 1-2, dode2003lossoffunctionmutationsin pages 1-2, men2020genotypicandphenotypic pages 5-8)

8. Temporal Development

8.1 Typical onset

Although the developmental defect is congenital, CHH/KS is often diagnosed in adolescence when puberty fails to start or progress. (dwyer2024classesandpredictors pages 3-4)

8.2 Progression and course

  • Most cases require long-term management, but a clinically important subset exhibits reversal (return of endogenous reproductive function). Reversal frequency estimates in recent sources range from ~10–15% in CHH (Dwyer 2024) to 5–20% across broader literature summaries (Vezzoli 2023) (dwyer2024classesandpredictors pages 3-4, vezzoli2023geneticarchitectureof pages 3-5).

8.3 Critical periods

The key biological “critical period” is embryonic GnRH neuron neurogenesis and early migration from the olfactory placode niche, as highlighted by the Fgf8/Fgfr1 hypomorph mouse data. (chung2023theinitiationand pages 2-3)

9. Inheritance and Population

9.1 Inheritance

  • Autosomal dominant inheritance is established for FGFR1-related KS/CHH with incomplete penetrance and variable expressivity; oligogenic inheritance can occur. (dode2003lossoffunctionmutationsin pages 1-2, goncalves2015novelfgfr1mutations pages 3-4, sayed2023paneltestingfor pages 2-3)

9.2 Epidemiology

  • Chu et al. (2023) report estimated KS prevalence of ~1/30,000 men and ~1/125,000 women, and state KS accounts for ~50% of IHH (chu2023mutationspectrumof pages 1-2).
  • CHH is reported to be about 4× more common in males in the 2024 reversal study background. (dwyer2024classesandpredictors pages 3-4)

9.3 Variant prevalence in CHH/IHH cohorts

Men et al. (2020) report the combined prevalence of FGFR1/FGF8/FGF17 mutations of 12.4% in a Chinese IHH cohort (men2020genotypicandphenotypic pages 1-2).

10. Diagnostics

10.1 Clinical criteria and hormonal testing

Dwyer et al. (Lancet Diabetes & Endocrinology; Apr 2024; https://doi.org/10.1016/S2213-8587(24)00028-7) define CHH in males as absent/incomplete puberty with low testosterone (<6 nmol/L) and low/inappropriately normal gonadotropins; partial puberty includes mean testicular volume ≥4 cc (dwyer2024classesandpredictors pages 3-4).

10.2 Imaging

  • MRI evaluation of the olfactory bulbs/tracts is a key diagnostic discriminator for KS. Xia et al. emphasize MRI findings and state MRI of olfactory bulbs/tracts contributes to diagnosis (xia2021twofemalespresenting pages 5-5).

10.3 Genetic testing strategy (2023–2024 “real-world” implementation)

  • Panel-based testing: Sayed & Howard (European Journal of Human Genetics; Dec 2023; https://doi.org/10.1038/s41431-022-01261-0) describe UK NHSE Genomic Medicine Service implementation of a curated CHH panel via PanelApp and note cohort studies showing an underlying variant is found in 21–51% of CHH/KS cases (sayed2023paneltestingfor pages 2-3).
  • WES/WGS: Xia et al. recommend WES as a priority in females with primary amenorrhea without secondary sex characteristics and note that WES can also indicate karyotype/chromosomal abnormalities and CNVs (xia2021twofemalespresenting pages 1-2, xia2021twofemalespresenting pages 5-5).
  • CNV analysis: Chu et al. employed CNV-seq and classified an 8p deletion spanning FGFR1 as pathogenic (chu2023mutationspectrumof pages 1-2).

10.4 Differential diagnosis

In females presenting primary amenorrhea, Xia et al. highlight the need for karyotype to exclude Turner syndrome and other chromosomal etiologies (both reported patients were 46,XX) and recommend focused olfactory history plus olfactory MRI (xia2021twofemalespresenting pages 1-2).

11. Outcome / Prognosis

11.1 Fertility prognosis

In male CHH, spermatogenesis and fertility are achievable in approximately ~75% of men treated with exogenous gonadotropins (FSH + hCG) or pulsatile GnRH, according to Dwyer 2024 background synthesis (dwyer2024classesandpredictors pages 3-4).

11.2 Reversal prognosis

  • Spontaneous reversal occurs in ~10–15% (Dwyer 2024) (dwyer2024classesandpredictors pages 3-4).
  • Dwyer 2024 further reports genetic/clinical associations: non-reversal patients were more likely to show oligogenicity than reversal patients (58.9% vs 29.3%) and baseline testicular volume positively predicted reversal (dwyer2024classesandpredictors pages 9-11).

11.3 Morbidity and quality of life impacts

While dedicated QoL instruments were not captured in the retrieved texts, Xia et al. reported osteoporosis/high fracture risk in females at diagnosis (DXA evidence), implying clinically significant morbidity from delayed diagnosis and untreated hypogonadism (xia2021twofemalespresenting pages 1-2).

12. Treatment

A structured treatment/applications table with outcomes, risks, MAXO suggestions, and clinical trial mappings is provided:

Treatment goal Intervention Typical candidates / sex Key outcomes / statistics from evidence Key risks / considerations Example trials / implementations Suggested MAXO terms
Puberty induction / virilization Testosterone replacement (IM or transdermal) Primarily adolescent or adult males with CHH/KS, including FGFR1-related disease Standard therapy to induce secondary sexual characteristics; does not induce fertility by itself. In male CHH more broadly, treatment improves sexual, bone, metabolic, and psychological health; testicular growth on testosterone may occasionally signal HPG-axis activation. Reversal of CHH has been observed after sex-steroid treatment in a subset of patients; overall spontaneous/therapy-associated reversal is ~10–15% (broader literature 5–20%) (dwyer2024classesandpredictors pages 3-4, vezzoli2023geneticarchitectureof pages 3-5, dwyer2024classesandpredictors pages 9-11) Requires long-term monitoring of pubertal progression, hematocrit, bone health, and possible later fertility planning; may mask spontaneous reversal unless washout is attempted. Genetic counseling is important because FGFR1-related disease can be transmitted to offspring (dwyer2024classesandpredictors pages 3-4, sayed2023paneltestingfor pages 2-3) Real-world standard endocrine care; Dwyer 2024 notes reversal has occurred after testosterone treatment in some men, supporting structured adult washout/monitoring in selected patients (dwyer2024classesandpredictors pages 3-4, dwyer2024classesandpredictors pages 9-11) MAXO: hormone replacement therapy; testosterone replacement
Puberty induction / uterine and bone health Estradiol replacement, later cyclic estrogen-progestin therapy Primarily adolescent or adult females with CHH/KS, including FGFR1-related disease Used to induce breast/uterine development and protect bone health. In two FGFR1-positive KS females, one patient was treated with estradiol valerate after diagnosis established by WES and olfactory MRI (xia2021twofemalespresenting pages 2-2) Requires gradual dose escalation, endometrial protection with progestin when appropriate, and bone-density follow-up; does not restore fertility by itself. In FGFR1-related disease, recurrence risk for offspring should be discussed (xia2021twofemalespresenting pages 2-5, xia2021twofemalespresenting pages 2-2) Case-level implementation in FGFR1-related female KS: Xia et al. used estradiol valerate in one patient after confirming de novo FGFR1 variant and olfactory bulb agenesis (xia2021twofemalespresenting pages 2-5, xia2021twofemalespresenting pages 2-2) MAXO: estrogen replacement therapy; progestin therapy
Fertility induction / spermatogenesis hCG followed by hCG + hMG or uFSH (combined gonadotropin therapy) Males desiring fertility; often used in CHH/KS including FGFR1-related cases In male CHH broadly, spermatogenesis and fertility are achievable in ~75% of men treated with exogenous gonadotropins or pulsatile GnRH. Men 2020 reported hCG/hMG markedly increased testicular size in mutation-positive patients. In FGFR1/FGF8/FGF17 mutation carriers, fertility is possible but mutation transmission risk remains (men2020genotypicandphenotypic pages 5-8, dwyer2024classesandpredictors pages 3-4) Months-to-years treatment; monitor testosterone, testicular volume, sperm counts, adverse effects. Genetic counseling is important for autosomal dominant FGFR1 variants; female partners may need reproductive counseling. Limited response may occur in severe cases (men2020genotypicandphenotypic pages 5-8, dwyer2024classesandpredictors pages 3-4) NCT02310074 compared pulsatile GnRH pump vs hCG alone 6 months then hCG+uFSH 12 months in 76 men; primary outcome partner pregnancy by 18 months; secondary outcomes included time to first sperm and sperm-density thresholds (NCT02310074 chunk 1) MAXO: chorionic gonadotropin therapy; follicle-stimulating hormone therapy; fertility treatment
Fertility induction / spermatogenesis Pulsatile GnRH / gonadorelin pump Males with hypothalamic CHH/KS; also some females for ovulation induction In male CHH broadly, pulsatile GnRH is an established fertility-induction strategy and contributes to the ~75% spermatogenesis/fertility success estimate when combined with gonadotropin-based evidence. In Xia 2021, one female FGFR1-positive KS patient received pulsatile gonadorelin pump therapy (dwyer2024classesandpredictors pages 3-4, xia2021twofemalespresenting pages 2-2) Pump burden, adherence, cost, need for specialized centers; monitor LH/FSH/testosterone or ovulation response. Appropriate in hypothalamic forms; not a substitute for genetic counseling regarding transmission (dwyer2024classesandpredictors pages 3-4, xia2021twofemalespresenting pages 2-5) NCT02310074: open-label phase 4 male IHH study of 18-month portable subcutaneous pulsatile GnRH pump vs gonadotropins, with pregnancy and spermatogenesis endpoints (NCT02310074 chunk 1) MAXO: gonadotropin-releasing hormone therapy; pulsatile hormone administration
Ovulation induction / pregnancy Subcutaneous pulsatile GnRH (gonadorelin acetate) via OmniPod / LutrePulse Women with hypogonadotropic hypogonadism seeking pregnancy NCT01976728 was a phase 3 multicenter double-blind randomized placebo-controlled study (39 women) testing 10, 15, or 20 µg/pulse. Primary endpoint: ovulation rate, defined by progesterone ≥6 ng/mL, positive β-hCG, or gestational sac on ultrasound. Secondary endpoints included clinical/biochemical pregnancy, LH surge, follicular development, estradiol/LH/FSH changes, and OHSS frequency (NCT01976728 chunk 1) Requires normal reproductive tract evaluation, partner semen assessment, and monitoring for ovarian response/OHSS. Practical burdens include pump use and close reproductive-endocrine follow-up (NCT01976728 chunk 2, NCT01976728 chunk 1) NCT01976728 (LutrePulse): phase 3, randomized, placebo-controlled ovulation-induction trial in women with HH; results posted 2021-03-03 (NCT01976728 chunk 1) MAXO: ovulation induction; gonadotropin-releasing hormone therapy; assisted reproduction
Rescue fertility strategy after poor gonadotropin response Switch to or trial of pulsatile GnRH after inadequate hCG/hMG response Selected males with CHH/KS who have poor spermatogenic response to combined gonadotropins 2024 literature highlights pulsatile GnRH as an alternative strategy for spermatogenesis in poor responders; rationale is restoration of physiologic pituitary stimulation rather than direct gonadotropin replacement. This is especially relevant in specialized male fertility programs (NCT02310074 chunk 1) Requires specialized expertise and pump access; evidence is evolving and not FGFR1-specific. Persistent infertility can still occur in severe congenital cases (NCT02310074 chunk 1) Supported by contemporary CHH treatment studies and by the design of NCT02310074 comparing pump therapy with gonadotropins (NCT02310074 chunk 1) MAXO: gonadotropin-releasing hormone therapy; infertility management
Bone / metabolic / general health support Early diagnosis plus sex-steroid replacement; monitor BMD and metabolic status Both sexes CHH management improves sexual, bone, metabolic, and psychological health. Xia 2021 reported osteoporosis/high fracture risk in affected females at diagnosis, underscoring the need for early replacement therapy and bone monitoring (xia2021twofemalespresenting pages 1-2, dwyer2024classesandpredictors pages 3-4) Delayed diagnosis worsens bone and psychosocial outcomes; ongoing DXA, vitamin D/calcium assessment, and lifestyle counseling may be needed. FGFR1 variants may also have broader metabolic implications, as defective FGFR1 signaling has been linked to lower insulin sensitivity in a 2024 human recall-by-genotype study (xia2021twofemalespresenting pages 1-2, dwyer2024classesandpredictors pages 3-4) Standard endocrine follow-up rather than disease-specific trial. 2024 FGFR1 human study suggests impaired FGFR1 signaling may contribute to early insulin resistance, supporting attention to metabolic monitoring in variant carriers (dwyer2024classesandpredictors pages 3-4) MAXO: bone mineral density monitoring; metabolic monitoring; supportive endocrine care
Prognostic / management strategy Structured treatment washout and reassessment for reversal Mostly adult males after puberty induction or fertility treatment CHH reversal occurs in ~10–15% of cases; Dwyer 2024 reports most confirmed washouts were after age 18 and that reversal can follow testosterone, gonadotropins, or pulsatile GnRH. Larger baseline testicular volume predicts reversal, whereas cryptorchidism and oligogenicity predict lower reversal likelihood (dwyer2024classesandpredictors pages 3-4, dwyer2024classesandpredictors pages 9-11) Must distinguish true reversal from temporary improvement; relapse can occur, so long-term monitoring is necessary. Genetic findings generally do not yet change first-line treatment, except for counseling implications (dwyer2024classesandpredictors pages 9-11) Dwyer 2024 multicenter cross-sectional study provides current evidence base for reversal monitoring and prognosis across referral centers (dwyer2024classesandpredictors pages 3-4, dwyer2024classesandpredictors pages 9-11) MAXO: treatment monitoring; endocrine function assessment; therapy withdrawal trial

Table: This table summarizes current treatment applications for FGFR1-related congenital hypogonadotropic hypogonadism/Kallmann syndrome and CHH more broadly, including puberty induction, fertility induction, bone/metabolic support, and reversal monitoring. It integrates quantitative outcomes, practical considerations, relevant trial examples, and suggested MAXO terms for knowledge-base annotation.

12.1 Puberty induction

  • Males: testosterone replacement to induce secondary sexual characteristics (dwyer2024classesandpredictors pages 3-4).
  • Females: estrogen replacement with later cyclic estrogen–progestin therapy; Xia et al. describe estradiol valerate therapy in a female KS patient (xia2021twofemalespresenting pages 2-2).

12.2 Fertility induction (real-world implementations)

  • Males: exogenous gonadotropins (hCG ± FSH/hMG) or pulsatile GnRH; Men et al. report that hCG/hMG increased testicular size in treated males and note reversal in a subset of IHH cases (men2020genotypicandphenotypic pages 5-8).
  • Females: pulsatile GnRH for ovulation induction.

12.3 Clinical trials (examples)

  • NCT02310074 (Shanghai Jiao Tong University School of Medicine; Phase 4; study start 2010; primary completion Jun 2014): compares pulsatile GnRH pump vs gonadotropin therapy in 76 men with IHH; primary endpoint partner pregnancy by 18 months; secondary endpoints include time to first sperm and sperm-density thresholds (ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT02310074) (NCT02310074 chunk 1).
  • NCT01976728 (Ferring; Phase 3; start 2014-04-01; completion 2018-02-23; results posted 2021-03-03): LutrePulse (gonadorelin acetate) delivered via OmniPod for ovulation induction in women with HH; primary endpoint ovulation rate and secondary pregnancy and follicular outcomes (ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT01976728) (NCT01976728 chunk 1).

12.4 Targeted/advanced therapeutics

No FGFR1 gene therapy or FGFR1-targeted molecular therapy trials for FGFR1-related CHH/KS were identified in the retrieved clinical trials set; current treatment is hormonal replacement and fertility induction.

13. Prevention

Primary prevention. Not applicable in the conventional sense for a monogenic developmental disorder.

Secondary prevention (early detection). Earlier recognition of delayed puberty/amenorrhea, structured evaluation of olfaction, and timely endocrine replacement can prevent downstream morbidity (e.g., low bone density) (xia2021twofemalespresenting pages 1-2).

Genetic counseling (tertiary/recurrence prevention). Because FGFR1-related CHH/KS is often autosomal dominant with incomplete penetrance and can be oligogenic, recurrence risk counseling is complex; modern panel testing and careful variant interpretation are emphasized as essential to counseling (sayed2023paneltestingfor pages 2-3, dode2003lossoffunctionmutationsin pages 1-2).

Suggested MAXO (prevention-related) terms: genetic counseling; carrier testing; cascade screening (supported conceptually by genetics and counseling emphasis in modern diagnostic reviews) (sayed2023paneltestingfor pages 2-3).

14. Other Species / Natural Disease

No naturally occurring veterinary disease analogs were retrieved in the provided texts. The strongest cross-species evidence is mechanistic/model-organism rather than naturally occurring disease.

15. Model Organisms

15.1 Mammalian models

Mouse hypomorphic models summarized by Chung & Tsai (2023) provide strong mechanistic evidence for FGF8/FGFR1 roles in GnRH neuron neurogenesis and survival (including ~90% GnRH neuron reduction in Fgfr1 hypomorphic newborns) (chung2023theinitiationand pages 2-3).

15.2 Invertebrate models

Dodé et al. cite C. elegans data where kal1 mis/overexpression produces an axon-branching phenotype dependent on heparan-sulfate sulfation, supporting conserved extracellular-matrix modulation relevant to the FGFR1 pathway context (dode2003lossoffunctionmutationsin pages 1-2).

15.3 Model limitations

Mouse and C. elegans models capture developmental neurobiology mechanisms but do not fully reproduce the human spectrum of incomplete penetrance, variable expressivity, oligogenic inheritance, and treatment-associated reversal.

High-priority recent developments (2023–2024) — curated summary

  1. Clinical diagnostic implementation: UK NHSE Genomic Medicine Service CHH panel curated via PanelApp; molecular diagnostic yield across cohorts 21–51%; key interpretive challenges are oligogenicity and incomplete penetrance (Dec 2023) (sayed2023paneltestingfor pages 2-3).
  2. Variant interpretation advance for FGFR1: regional enrichment of FGFR1 missense variants across protein domains used to strengthen ACMG/AMP evidence and reclassify 37% of FGFR1 missense VUS (Oct 2023) (xu2023howhumangenetic pages 1-2).
  3. Clinical course/reversal predictors: multicenter study standardizing reversal definitions and identifying predictors (cryptorchidism negative; baseline testicular volume positive; oligogenicity associated with non-reversal), while reaffirming fertility success estimates and reversal frequency (Apr 2024) (dwyer2024classesandpredictors pages 3-4, dwyer2024classesandpredictors pages 9-11).

Key abstract quotes (for knowledge-base evidence items)

  • Dodé et al. (2003): “Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome.” (dode2003lossoffunctionmutationsin pages 1-2)
  • Chu et al. (2023): KS prevalence and phenotype spectrum statements; KS described as IHH subtype with anosmia/hyposmia and multiple associated anomalies (chu2023mutationspectrumof pages 1-2).
  • Xia et al. (2021): “Magnetic resonance imaging showed dysplastic or absent olfactory bulbs and tracts.” and recommendation that WES “should be a priority” in primary amenorrhea without secondary sex characteristics (xia2021twofemalespresenting pages 1-2).

Data gaps and limitations of this tool-run

  • ICD-10/ICD-11, MeSH, Orphanet IDs were not present in the retrieved full-text corpus for FGFR1-related CHH/KS and therefore are not provided here.
  • FGFR1-specific penetrance estimates (numerical) and variant allele frequencies in gnomAD were not retrievable with the current evidence set.
  • FGFR1-specific genotype–treatment response statistics are limited; most treatment outcomes are reported at CHH syndrome level rather than gene-stratified.

References

  1. (chu2023mutationspectrumof pages 1-2): Guoming Chu, Pingping Li, Qian Zhao, Rong He, and Yanyan Zhao. Mutation spectrum of kallmann syndrome: identification of five novel mutations across anos1 and fgfr1. Reproductive Biology and Endocrinology : RB&E, Mar 2023. URL: https://doi.org/10.1186/s12958-023-01074-w, doi:10.1186/s12958-023-01074-w. This article has 7 citations.

  2. (dode2003lossoffunctionmutationsin pages 1-2): Catherine Dodé, Jacqueline Levilliers, Jean-Michel Dupont, Anne De Paepe, Nathalie Le Dû, Nadia Soussi-Yanicostas, Roney S. Coimbra, Sedigheh Delmaghani, Sylvie Compain-Nouaille, Françoise Baverel, Christophe Pêcheux, Dominique Le Tessier, Corinne Cruaud, Marc Delpech, Frank Speleman, Stefan Vermeulen, Andrea Amalfitano, Yvan Bachelot, Philippe Bouchard, Sylvie Cabrol, Jean-Claude Carel, Henriette Delemarre-van de Waal, Barbara Goulet-Salmon, Marie-Laure Kottler, Odile Richard, Franco Sanchez-Franco, Robert Saura, Jacques Young, Christine Petit, and Jean-Pierre Hardelin. Loss-of-function mutations in fgfr1 cause autosomal dominant kallmann syndrome. Nature Genetics, 33:463-465, Mar 2003. URL: https://doi.org/10.1038/ng1122, doi:10.1038/ng1122. This article has 1039 citations and is from a highest quality peer-reviewed journal.

  3. (chung2023theinitiationand pages 2-3): Wilson CJ Chung and Pei-San Tsai. The initiation and maintenance of gonadotropin-releasing hormone neuron identity in congenital hypogonadotropic hypogonadism. Frontiers in Endocrinology, Apr 2023. URL: https://doi.org/10.3389/fendo.2023.1166132, doi:10.3389/fendo.2023.1166132. This article has 12 citations.

  4. (xu2023howhumangenetic pages 1-2): Wanxue Xu, Lacey Plummer, Stephanie B. Seminara, Ravikumar Balasubramanian, and Margaret F. Lippincott. How human genetic context can inform pathogenicity classification: fgfr1 variation in idiopathic hypogonadotropic hypogonadism. Human Genetics, 142:1611-1619, Oct 2023. URL: https://doi.org/10.1007/s00439-023-02601-w, doi:10.1007/s00439-023-02601-w. This article has 4 citations and is from a peer-reviewed journal.

  5. (vezzoli2023geneticarchitectureof pages 3-5): Valeria Vezzoli, Faris Hrvat, Giovanni Goggi, Silvia Federici, Biagio Cangiano, Richard Quinton, Luca Persani, and Marco Bonomi. Genetic architecture of self-limited delayed puberty and congenital hypogonadotropic hypogonadism. Frontiers in Endocrinology, Jan 2023. URL: https://doi.org/10.3389/fendo.2022.1069741, doi:10.3389/fendo.2022.1069741. This article has 26 citations.

  6. (sayed2023paneltestingfor pages 2-3): Yasmin Al Sayed and Sasha R. Howard. Panel testing for the molecular genetic diagnosis of congenital hypogonadotropic hypogonadism – a clinical perspective. European Journal of Human Genetics, 31:387-394, Dec 2023. URL: https://doi.org/10.1038/s41431-022-01261-0, doi:10.1038/s41431-022-01261-0. This article has 32 citations and is from a domain leading peer-reviewed journal.

  7. (men2020genotypicandphenotypic pages 1-2): Meichao Men, Jiayu Wu, Yaguang Zhao, Xiaoliang Xing, Fang Jiang, Ruizhi Zheng, and Jia-Da Li. Genotypic and phenotypic spectra of fgfr1, fgf8, and fgf17 mutations in a chinese cohort with idiopathic hypogonadotropic hypogonadism. Fertility and Sterility, 113:158-166, Jan 2020. URL: https://doi.org/10.1016/j.fertnstert.2019.08.069, doi:10.1016/j.fertnstert.2019.08.069. This article has 30 citations and is from a highest quality peer-reviewed journal.

  8. (goncalves2015novelfgfr1mutations pages 1-2): Catarina Gonçalves, Margarida Bastos, Duarte Pignatelli, Teresa Borges, José M. Aragüés, Fernando Fonseca, Bernardo D. Pereira, Sílvia Socorro, and Manuel C. Lemos. Novel fgfr1 mutations in kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism: evidence for the involvement of an alternatively spliced isoform. Fertility and Sterility, 104:1261-1267.e1, Nov 2015. URL: https://doi.org/10.1016/j.fertnstert.2015.07.1142, doi:10.1016/j.fertnstert.2015.07.1142. This article has 24 citations and is from a highest quality peer-reviewed journal.

  9. (dwyer2024classesandpredictors pages 3-4): Andrew A Dwyer, Isabella R McDonald, Biagio Cangiano, Luca Giovanelli, Luigi Maione, Leticia F G Silveira, Taneli Raivio, Ana Claudia Latronico, Jacques Young, Richard Quinton, Marco Bonomi, Luca Persani, Stephanie B Seminara, and Christopher S Lee. Classes and predictors of reversal in male patients with congenital hypogonadotropic hypogonadism: a cross-sectional study of six international referral centres. The Lancet Diabetes & Endocrinology, 12:257-266, Apr 2024. URL: https://doi.org/10.1016/s2213-8587(24)00028-7, doi:10.1016/s2213-8587(24)00028-7. This article has 17 citations and is from a highest quality peer-reviewed journal.

  10. (xia2021twofemalespresenting pages 1-2): Junke Xia, Xiao Luo, Xinyuan Zhang, and Xiangdong Kong. Two females presenting primary amenorrhea diagnosed with kallmann syndrome caused by novel fgfr1 variants. Journal of Obstetrics and Gynaecology Research, 47:3727-3731, Aug 2021. URL: https://doi.org/10.1111/jog.14966, doi:10.1111/jog.14966. This article has 1 citations and is from a peer-reviewed journal.

  11. (goncalves2015novelfgfr1mutations pages 3-4): Catarina Gonçalves, Margarida Bastos, Duarte Pignatelli, Teresa Borges, José M. Aragüés, Fernando Fonseca, Bernardo D. Pereira, Sílvia Socorro, and Manuel C. Lemos. Novel fgfr1 mutations in kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism: evidence for the involvement of an alternatively spliced isoform. Fertility and Sterility, 104:1261-1267.e1, Nov 2015. URL: https://doi.org/10.1016/j.fertnstert.2015.07.1142, doi:10.1016/j.fertnstert.2015.07.1142. This article has 24 citations and is from a highest quality peer-reviewed journal.

  12. (pitteloud2010complexgeneticsin pages 9-10): Nelly Pitteloud, Sadia Durrani, Taneli Raivio, and Gerasimos P. Sykiotis. Complex genetics in idiopathic hypogonadotropic hypogonadism. Frontiers of hormone research, 39:142-53, Apr 2010. URL: https://doi.org/10.1159/000312700, doi:10.1159/000312700. This article has 92 citations and is from a peer-reviewed journal.

  13. (dwyer2024classesandpredictors pages 9-11): Andrew A Dwyer, Isabella R McDonald, Biagio Cangiano, Luca Giovanelli, Luigi Maione, Leticia F G Silveira, Taneli Raivio, Ana Claudia Latronico, Jacques Young, Richard Quinton, Marco Bonomi, Luca Persani, Stephanie B Seminara, and Christopher S Lee. Classes and predictors of reversal in male patients with congenital hypogonadotropic hypogonadism: a cross-sectional study of six international referral centres. The Lancet Diabetes & Endocrinology, 12:257-266, Apr 2024. URL: https://doi.org/10.1016/s2213-8587(24)00028-7, doi:10.1016/s2213-8587(24)00028-7. This article has 17 citations and is from a highest quality peer-reviewed journal.

  14. (men2020genotypicandphenotypic pages 5-8): Meichao Men, Jiayu Wu, Yaguang Zhao, Xiaoliang Xing, Fang Jiang, Ruizhi Zheng, and Jia-Da Li. Genotypic and phenotypic spectra of fgfr1, fgf8, and fgf17 mutations in a chinese cohort with idiopathic hypogonadotropic hypogonadism. Fertility and Sterility, 113:158-166, Jan 2020. URL: https://doi.org/10.1016/j.fertnstert.2019.08.069, doi:10.1016/j.fertnstert.2019.08.069. This article has 30 citations and is from a highest quality peer-reviewed journal.

  15. (chung2023theinitiationand pages 6-6): Wilson CJ Chung and Pei-San Tsai. The initiation and maintenance of gonadotropin-releasing hormone neuron identity in congenital hypogonadotropic hypogonadism. Frontiers in Endocrinology, Apr 2023. URL: https://doi.org/10.3389/fendo.2023.1166132, doi:10.3389/fendo.2023.1166132. This article has 12 citations.

  16. (miraoui2013mutationsinfgf17 pages 3-3): Hichem Miraoui, Andrew A. Dwyer, Gerasimos P. Sykiotis, Lacey Plummer, Wilson Chung, Bihua Feng, Andrew Beenken, Jeff Clarke, Tune H. Pers, Piotr Dworzynski, Kimberley Keefe, Marek Niedziela, Taneli Raivio, William F. Crowley, Stephanie B. Seminara, Richard Quinton, Virginia A. Hughes, Philip Kumanov, Jacques Young, Maria A. Yialamas, Janet E. Hall, Guy Van Vliet, Jean-Pierre Chanoine, John Rubenstein, Moosa Mohammadi, Pei-San Tsai, Yisrael Sidis, Kasper Lage, and Nelly Pitteloud. Mutations in fgf17, il17rd, dusp6, spry4, and flrt3 are identified in individuals with congenital hypogonadotropic hypogonadism. American journal of human genetics, 92 5:725-43, May 2013. URL: https://doi.org/10.1016/j.ajhg.2013.04.008, doi:10.1016/j.ajhg.2013.04.008. This article has 340 citations and is from a highest quality peer-reviewed journal.

  17. (chung2023theinitiationand media 627f77bc): Wilson CJ Chung and Pei-San Tsai. The initiation and maintenance of gonadotropin-releasing hormone neuron identity in congenital hypogonadotropic hypogonadism. Frontiers in Endocrinology, Apr 2023. URL: https://doi.org/10.3389/fendo.2023.1166132, doi:10.3389/fendo.2023.1166132. This article has 12 citations.

  18. (xia2021twofemalespresenting pages 2-5): Junke Xia, Xiao Luo, Xinyuan Zhang, and Xiangdong Kong. Two females presenting primary amenorrhea diagnosed with kallmann syndrome caused by novel fgfr1 variants. Journal of Obstetrics and Gynaecology Research, 47:3727-3731, Aug 2021. URL: https://doi.org/10.1111/jog.14966, doi:10.1111/jog.14966. This article has 1 citations and is from a peer-reviewed journal.

  19. (xia2021twofemalespresenting pages 5-5): Junke Xia, Xiao Luo, Xinyuan Zhang, and Xiangdong Kong. Two females presenting primary amenorrhea diagnosed with kallmann syndrome caused by novel fgfr1 variants. Journal of Obstetrics and Gynaecology Research, 47:3727-3731, Aug 2021. URL: https://doi.org/10.1111/jog.14966, doi:10.1111/jog.14966. This article has 1 citations and is from a peer-reviewed journal.

  20. (xia2021twofemalespresenting pages 2-2): Junke Xia, Xiao Luo, Xinyuan Zhang, and Xiangdong Kong. Two females presenting primary amenorrhea diagnosed with kallmann syndrome caused by novel fgfr1 variants. Journal of Obstetrics and Gynaecology Research, 47:3727-3731, Aug 2021. URL: https://doi.org/10.1111/jog.14966, doi:10.1111/jog.14966. This article has 1 citations and is from a peer-reviewed journal.

  21. (NCT02310074 chunk 1): Guang Ning. Efficacy and Safety of Pulsatile Gonadotropin Releasing Hormone Pump Treatment in Patients With Idiopathic Hypogonadotropic Hypogonadism. Shanghai Jiao Tong University School of Medicine. 2010. ClinicalTrials.gov Identifier: NCT02310074

  22. (NCT01976728 chunk 1): LutrePulse Hypogonadotropic Hypogonadism. Ferring Pharmaceuticals. 2014. ClinicalTrials.gov Identifier: NCT01976728

  23. (NCT01976728 chunk 2): LutrePulse Hypogonadotropic Hypogonadism. Ferring Pharmaceuticals. 2014. ClinicalTrials.gov Identifier: NCT01976728